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 Acetaminophen (N-acetyl-p-aminophenol, APAP) is one of the most widely used 
over-the-counter antipyretic analgesic medications. It is safe at therapeutic doses, but an 
overdose can result in severe hepato-nephrotoxicity, a leading cause of drug-induced 
acute liver failure in the U.S. Although a few different mechanisms have been proposed 
for APAP-induced toxicity, a significant amount of evidence has pointed to the potential 
involvement of oxidative stress in acetaminophen toxicity. Depletion of glutathione 
(GSH) is one of the initiating steps in APAP-induced toxicity; therefore, one strategy for 
restricting organ damage is to restore GSH levels by using GSH prodrugs like N-
acetylcysteine (NAC). Although NAC is the treatment of choice for APAP-induced 
toxicity, fairly high doses and longer treatment times are required due to its poor 
bioavailability. In addition, oral and IV administration of NAC in a hospital setting are 
laborious and costly. With limited therapeutic options, other than NAC, it is important to 
develop therapeutic alternatives to effectively protect against APAP-induced toxicity and 
to improve treatment outcomes and prevent death. Therefore, we studied the protective 
effects of N-acetylcysteine amide (NACA), a novel antioxidant with higher 
bioavailability, and compared it with NAC in APAP-induced toxicity in C57BL/6 mice. 
Our results showed that a lower dose of NACA is better than NAC in combating 
oxidative stress and protecting against APAP-induced damage. The higher efficiency of 
NACA, in protecting against APAP-induced toxicity, suggests that NACA can be 
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   Acetaminophen (APAP), also known as paracetamol in Britain, is derived from 
the chemical compound named para-acetylaminophenol.[1] It is an analgesic and 
antipyretic drug that is widely used by approximately 43 million adults in the USA every 
week. [2] It is safe at a therapeutic dose and is available over-the-counter as a single 
formula and in combination with other medications, as well as by prescription when it is 
combined with opioids.[2] However, an overdose results in hepatic toxicity, the most 
common cause of drug-induced liver injury,[3-6] that has led to nearly 80,000 emergency 
room visits and around 30,000 hospitalizations annually in the USA.[7, 8] The first case of 
APAP hepatotoxicity was reported in 1966 and concerns about APAP toxicity have been 
ongoing since then.[9] In fact, the Food and Drug Administration (FDA) requested that 
manufacturers limit the amount of APAP in combination products to no more than 325 
mg in each tablet.[2] 
Increased attention is being given to APAP toxicity, in the medical setting, as 
over doses of APAP appear to be common in the USA, despite the known risks of 
toxicity. Without immediate treatment of an overdose, APAP toxicity leads to liver and 
kidney failure and death. N-acetylcysteine (NAC), a GSH precursor, [10] is currently the 
only FDA approved antidote for this toxicity. NAC restores GSH levels by reducing 
extracellular cystine to cysteine, a GSH precursor, and increases the synthesis of GSH, 
thus helping in the detoxification of the reactive metabolite and the scavenging of free 
radicals.[11-13] Additionally, NAC supplies mitochondrial energy substrates in the Krebs 
cycle and restores hepatic adenosine triphosphate (ATP) levels by providing excess 
amino acid (not needed for GSH synthesis) and uses it as energy substrates. [11-13] 
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Thereby, NAC helps to maintain a balance between reactive species and the antioxidant 
defense system in the body. However, high doses of NAC are required due to its low 
bioavailability since the carboxyl group loses its proton at a physiological pH of 7.35-
7.45, making NAC negatively charged. [14] This impedes the passing of NAC through the 
biological membranes, which increases the risk of side effects and the costs of treatment. 
Martello et al. [15] reported a cost analysis that compared actual costs for patients who 
received oral or IV NAC.[16] Overall health care cost (median cost) of IV NAC was 
reported as $7,607.82, versus $18,287.63 for oral NAC, with a median length of stay of 5 
days versus 7 days, respectively. The decreased cost of treatment and a shorter hospital 
stay have been used to justify approval of the use of an IV NAC. In addition to that, the 
side effects that accompany a high dose of IV NAC are similar to those of a clinical 
presentation of true anaphylaxis that includes rash, pruritus, angioedema, bronchospasm, 
and (rarely) hypotension. This may require discontinuation or delay in providing 
treatment. [17] Oral administration of NAC has been associated with vomiting and 
diarrhea, along with an unpleasant odor. Therefore, it would be of great value to 
introduce a safe and more effective drug that requires a shorter treatment time without 
these adverse side effects. Although, many investigators are exploring and endeavoring to 
introduce different compounds that can be active against the toxicity induced by APAP, 
most of those compounds are administered prior to APAP toxicity [18-25],which does not 
give an exact picture of their antidotal effect. 
N-acetylcysteine amide (NACA) is a modified form of NAC in which the 
carboxyl group is replaced with an amide that increases its lipophilicity.[14] This allows 
NACA to easily cross cell membranes and to require lower doses than NAC, which may 
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overcome the adverse side effects of NAC. The enhanced ability of NACA over NAC to 
penetrate cells was shown in my previously published study using HepaRG as the hepatic 
cell line.[26] NACA is a thiol antioxidant that enhances cellular antioxidant defense 
mechanisms and acts as a precursor to GSH. It can also promote intracellular 
detoxification and act directly as a free radical scavenger. Promising results with NACA, 
in treating various oxidative stress-related disorders, [27-31] as well as its encouraging 
effects on toxicity induced by APAP in the HepaRG cell line, inspired us to investigate 
these effects in an animal model. 
The purpose of this study was to investigate and determine the therapeutic effect 
of NACA against APAP-induced toxicity of various organs in an animal model, and to 
compare that with the effect of NAC. In this study, I used a mouse rather than a rat model 
for the experiment because Mitchell McGill and his group showed that rats are more 
resistant to APAP hepatotoxicity than mice.[32] This is due to a reduced mitochondrial 
protein binding that limits mitochondrial dysfunction, oxidative stress, and peroxynitrite 
formation and, therefore, does not show the exact picture of the toxicity induced by 
APAP. Accordingly, I used C57BL/6 mice, a well-known strain, that is commonly used 








2. LITERATURE REVIEW 
 
  
2.1. HISTORY OF ACETAMINOPHEN 
Acetaminophen (APAP) was discovered by chance and Mata Jozwial et al. 
published an account of that discovery in their paper. “In the ‘80s of the 19th century, two 
young doctors at the University of Strasburg, in order to eradicate worms, by mistake 
dispensed acetanilide to a patient instead of naphthalene. They noticed that the drug had 
a small impact on intestinal parasites; however, it significantly decreased high 
temperature. Young doctors - Arnold Chan and Paul Heppa - quickly published their 
discovery and acetanilide was introduced into medical practice in 1886 under the name 
of antifebrin. Soon it appeared that, although the production of this drug was very cheap, 
acetanilide could not be used as an antipyretic medicament due to its high toxicity, the 
most alarming of which was methemoglobinemia. This resulted in a great deal of 
research on less toxic derivatives of acetanilide. Phenacetin and N-acetyl-p-aminophenol 
appeared to be the most satisfying compounds, which had been earlier synthesized by 
Harmon Northrop Morse in 1878. The first clinical trials with those two acetanilide 
derivatives were performed by a German pharmacologist Joseph von Mering. On the 
basis of the obtained results, a faulty conclusion was drawn that paracetamol was 
characterized by high toxicity similar to acetanilide, therefore phenacetin was the first 
derivative to be introduced into medical practice in 1887. Phenacetin was widely used in 
analgesic mixtures until the time when it was associated with the development of 
analgesic nephropathy after a prolonged usage. In Poland, phenacetin was used as a 
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component of very popular and available everywhere analgesic ëítablets with the crossíí. 
In fact, acetaminophen became popular in 1948 when Bernard Brodie and Julius Axelrod 
demonstrated that paracetamol was the main active metabolite of acetanilide and 
phenacetin was responsible for their analgesic and antipyretic action and that 
methemoglobinemia was induced by another metabolite, phenylhydroxyl- amine. That 
discovery revolutionized the pharmaceutical market of analgesic drugs and since then 
paracetamol has started its staggering career.”[34] Now, it is included in the WHO Model 
List of Essential Medicines. 
2.2. ACETAMINOPHEN FACTS AND TOXICITY SIGNIFICANCE 
The Food and Drug Administration (FDA) approved the use of APAP in 1950 and 
as an over-the-counter medication in 1985.[35] In 2005, consumers purchased more than 
28 billion doses of products containing APAP, with the hydrocodone–acetaminophen 
combination product being the most frequently prescribed drug [35], and 165,000 cases of 
overdose being reported in the United States alone.[36] It is widely used by approximately 
43 million adults in this country every week, [2] leading to nearly 80,000 emergency room 
visits and around 30,000 hospitalizations annually.[7, 8] The first case of APAP 
hepatotoxicity was reported in 1966 and concerns about APAP toxicity have been 
ongoing since then.[9] The kidney is the second target organ of APAP toxicity, after the 
liver.[37] Studies have reported renal dysfunction in 1%-2% of the patients who overdosed 
on APAP. [36] In 2009, the FDA required that nonprescription and prescription APAP-




hepatotoxicity.[38, 39] In addition, they recently requested that manufacturers limit the 
amount of APAP in combination products to no more than 325 mg in each tablet. [2] 
2.3. ACETAMINOPHEN MECHANISM OF ACTION 
 Despite the widespread use of APAP for over 60 years in the United States, its 
mechanism of action has not been fully understood until now. The primary mechanism of 
action is believed to be similar to that of nonsteroidal anti-inflammatory drugs (NSAIDs), 
by inhibiting the conversion of arachidonic acid (AA) into prostaglandin H (PGH2), a 
local hormone that is  associated with pain, fever, and inflammation.[40] This conversion 
is catalyzed by prostaglandin H synthase (PGHS), referred to as cyclooxygenase (COX), 
which has two isoenzymes (COX-1 and COX-2). PGHS is a bifunctional enzyme and 
possesses two different enzymatic activities: cyclooxygenase and peroxidase (POX). The 
conversion of AA to PGH2 involves two reactions: cyclization of AA to unstable 15-
hydroxyperoxide (PGG2) with the involvement of a cyclooxygenase component, and 
double oxidation in positions 9 and 11; whereas the reduction of the PGG2 molecule to 
its 15-hydroxy analogue  (unstable structure of PGH2) takes place due to peroxidase 
activity of PGHS (POX). APAP does inhibit COX activity, although its mechanism is 
different from that of NSAIDs. APAP does not appear to act as a traditional NSAID, and 
selective COX-2 inhibitors inhibit cyclooxygenase by competing with arachidonic acid 
for the active site of the enzyme. APAP reduces the enzyme to an inactive form by acting 
as a factor that reduces a ferryl protoporphyrin IX radical cation within the peroxidase 
site of the PGHS enzyme. The selectivity of paracetamol appears to be based on peroxide 




 A third COX isozyme (COX-3), a COX enzyme isoform encoded by the COX-1 
gen, contains additional 30-34 amino acids. Although COX-3 is inhibited by APAP, it 
does not function in human organisms. For this reason, COX-3 has been discounted as a 
cause of APAP-induced analgesia in humans. [34, 41] 
Other studies have suggested that APAP is acting by modulation of the body’s 
endocannabinoid system. APAP deacetylates to p-aminophenol that reacts with 
arachidonic acid (AA) by fatty acid amide hydrolase (FAAH), resulting in the formation 
of active metabolite N-arachidonoylphenolamine (AM404).[34] AM404 acts indirectly to 
increase the activity of the endocannabinoid system. These substances can both modulate 
a serotonergic descending pain pathway and lower body temperature. At the same time, 
AM404 has been found to inhibit COX-1 and COX-2 enzymes at different 
concentrations. This may be used to explain the inhibitory action of APAP on COX 
enzymes in the CNS as well.[42, 43] Other investigators have suggested inhibition of 
nitrogen oxide formation as a mechanism of analgesic action by APAP. APAP directly 
inhibits N-methyl-D-aspartate (NMDA) receptors, blocks substance P-dependent 
synthesis of nitric oxide (an important neurotransmitter in the nociceptive processes) 
through the L-arginine-nitric oxide pathway, and reduces nociception.[34, 40] 
2.4. ACETAMINOPHEN TOXICITY 
 2.4.1. Acetaminophen Mechanism of Toxicity. The liver is the target organ for 
APAP toxicity because this is where it is detoxified (Figure 2.1). It is noted that drug-
induced hepatotoxicity is one of the major causes for withdrawal of drugs from the 
market.[44] Although the exact mechanism of the action of APAP is unclear, and remains 
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to be discovered, its metabolism is well known and characterized (Figure 2.2). APAP is 
mainly metabolized by glucuronidation, sulfation, and oxidation by cytochrome P450 
(CYP) to the reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI) [45-47] (Figure 
2.3).  At therapeutic doses, APAP is safe, with around 90-95% of the APAP being 
glucuronidated or sulfated in the liver, and then excreted. A small fraction of APAP 
remains unchanged and is also excreted in the urine. The remaining 5% -10%, 
metabolized by CYP (including CYP1A2, CYP3A4, and mainly CYP2E1) to the 
electrophilic intermediate NAPQI, is toxic, but it can be neutralized by conjugation with 
glutathione (GSH) to form GSH-adduct which is mainly excreted in bile. However, after 
an overdose of APAP, the formation of NAPQI exceeds the detoxification capacity of 
GSH, which leads to NAPQI accumulation. 
NAPQI has been known as the toxic metabolite of APAP, since the early 1980s, 
through the two-electron oxidation of APAP to a reactive quinone. CYP2E1 is a major 
isozyme that is responsible for NAPQI formation and is largely concentrated in the 
centrilobular region of the liver that corresponds to the site of APAP-induced toxicity.[48] 
Walubo et al. showed that inhibition of CYP3A4, 2E1, and 1A2, with a cocktail of 
ketoconazole, isoniazid, and caffeine, effectively prevents APAP toxicity in rats.[49] 
CYP2E1 knockout mice were found to be less susceptible to APAP-induced toxicity.[50] 
Toxicity of NAPQI was evaluated by dosing the hepatic (HepaRG) cell line with NAPQI 
and evaluating cell viability, which showed a drastic decrease in cell viability.[26] NAPQI 
is rapidly conjugated at the 3 position by GSH and excreted in the bile. This conjugation 
can proceed in either an enzymatic or non-enzymatic pathway. The enzymatic reaction is 
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catalyzed by the glutathione S-transferase enzymes (GST) that are heavily localized in 
the centrilobular region of the liver, although they are found throughout the liver.[48] 
NAPQI is an electrophilic compound that reacts with the nucleophilic sulphydryl 
group. An overdose of APAP results in the excess formation of NAPQI, which binds to 
the protein following a massive decrease in the amount of GSH.[51-53] Although cysteine 
is the major target for binding, lysine binding has been reported after APAP toxicity. This 
protein adduct can be measured in samples from intoxicated patients. Protein binding 
(mainly to mitochondrial protein) leads to mitochondrial dysfunction, which is reported 
to be a main step in toxicity.[54] NAPQI binding results in the inhibition of both 
complexes I and II in the mitochondrial respiratory chain, which disrupts the proton 
gradient that is necessary for the production of adenosine triphosphate (ATP). At the 
same time, NAPQI directly adducts ATP synthase, which leads to the inhibition of ATP 
production as well.[55] As a subsequent event, reactive oxygen and peroxynitrite are 
formed inside the mitochondria, as a result of mitochondria dysfunction, and GSH 
depletion proceeds to ROS generation as well.[56-58]  The production of peroxynitrite leads 
to protein nitration and is a precursor to mitochondrial permeability transition (MPT). 
Protein nitration is predominantly localized to the centrilobular region of the liver, which 
is consistent with APAP toxicity. Peroxynitrite also directly induces mitochondrial 
damage, as indicated by reduction of intact mitochondrial DNA and nitrotyrosine protein 
adducts localized to the mitochondria following APAP toxicity. Oxidant stress is 
involved in the activation of the c-jun-N-terminal kinase (JNK) pathway.[59, 60] It 
eventually triggers the opening of the MPT pore, resulting in collapse of the 
mitochondrial membrane potential. Furthermore, fragmentation of DNA has been 
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observed, preventing cell recovery and regeneration, and contributing to necrotic cell 
death in APAP toxicity. Inhibition of JNK by the inhibitor leflunomide reduces 
mitochondrial cytochrome c release following an APAP overdose (Figure 2.4). 
The kidney is the second organ affected by an APAP overdose (Figure 2.5). It 
receives a large supply of blood and contains specialized transport processes for 
concentrating and secreting drugs, as well as containing an active enzyme system to 
metabolically activate drugs.[61, 62] The mechanism of toxicity in the kidney is less clearly 
understood, as compared to the liver, although several potential mechanisms of renal 
toxicity are proposed in the literature. 
 When an overdose of APAP is administered, the metabolic pathways in the liver 
become saturated, which allows large amounts of unmetabolized APAP to reach the 
kidneys.[22] APAP-nephrotoxicity is due to metabolic activation of APAP by renal P450, 
a similar mechanism proposed for hepatotoxicity.[63-66] The severity of renal damage is 
significantly reduced by administration of piperonyl butoxide (a CYP inhibitor). [67] 
Another study showed that, when an animal is pre-treated with 3-methylcholanthrene 
(CYP induced in the liver only), APAP-induced hepatic necrosis occurred, while the 
kidneys were not affected, which suggested that the toxic metabolite was formed in situ 
in the kidneys.[68] Another possible mechanism of APAP toxicity is related to 
prostaglandin endoperoxidase synthetase (PGES). [67-69] PGES is an enzyme found in the 
kidneys that activates APAP to NAPQI in the medulla, where it is more pronounced, in 
contrast to CYP, which plays a more important role in the cortex. NAPQI conjugates to 
the protein of the proximal tubule that may initiate cell death. Moreover, N-deacetylation 
of APAP produces aminophenol, which is a nephrotoxic metabolite that could start redox 
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cycling in the kidney.[67, 69, 70] NAPQI-GSH conjugate is excreted into bile, reabsorbed in 
the small intestine, and transported to the kidneys, where it is degraded by ϒ-GT to 
NAPQI-cysteine. It was proposed that NAPQI-cysteine could form a reactive 
intermediate formed by C-S-lyase, instead of being conjugated to an acetyl group and 
excreted in the urine as the mercapturic acid conjugate.[71] 
 
 
                                                http://www.studydroid.com/printerFriendlyViewPack.php?packId=179082 
 
Figure 2.1. Localization of APAP toxicity in the centrilobular region (zone 3) of a liver 






Figure 2.2. Metabolism of acetaminophen (APAP) 
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Figure 2.5. Site of toxicity of acetaminophen (APAP) in the kidney 
 
2.4.2. Oxidative Stress in Acetaminophen Toxicity. Oxidative stress takes place 
when the balance between antioxidants and free radicals is broken; drugs and 
environmental toxins generally induce that. It is known to be involved in the propagation 
of cell injury induced by an APAP overdose and is regarded as a mechanism of hepato-
renal toxicity.[72-81] Metabolism of APAP to NAPQI and its detoxification by GSH lead to 
severe depletion of GSH (stored in the liver and kidneys), thereby inducing ROS. In 
addition, a consequence of that event is excessive NAPQI binding to mitochondrial 
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protein. This leads to mitochondrial dysfunction that results in generation of reactive 
oxygen/nitrogen species as well. A high level of ROS is known to cause impairment of 
the antioxidant defense system that subsequently leads to oxidative stress. Oxidative 
stress, in turn, induces various deleterious actions, including lipid peroxidation, protein 
oxidation, and DNA fragmentation. Many investigators, who have evaluated the effects 
of natural antioxidants in preventing or treating APAP toxicity, have shown positive 
effects which confirm the role of oxidative stress.[20-24, 33, 80] 
 Glutathione (GSH) is a tripeptide with a gamma peptide linkage between the 
amine group of cysteine, which is attached by normal peptide linkage to a glycine, and 
the carboxyl group of the glutamate side-chain.[82] It is synthesized by the action of the 
two-enzymatic processes, γ-glutamylcysteine synthetase (γ-GCS) to link the amino acids 
of glutamate and cysteine together through a gamma peptide bond to form γ-
glutamylcysteine. This is followed by further reaction of γ-glutamylcysteine with glycine 
to form glutathione, which is catalyzed by γ-glutathione synthetase (Figure 2.6). γ-GCS is 
the rate limiting step and it depends on the availability of cysteine, the sulfur amino acid 
precursor. GSH has a sulfhydryl group and acts as a reducing agent and antioxidant. It is 
converted to its oxidized form, glutathione disulfide (GSSG), when it reacts directly with 
free radicals (Figure 2.7). GSSG can be reduced back to GSH by a nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent enzyme, glutathione reductase (GR). [82] 
The ratio of GSH/GSSG is a determinant of the redox status of biological systems, so any 
defect in the level of GSSG to GSH has a pronounced effect on this ratio.  GSH is known 
to be involved either directly or indirectly in a number of biological phenomena and is 
mainly responsible for maintaining cellular redox status in endothelial cells. GSH 
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scavenges free radicals (R•) and other reactive oxygen species (ROS), and neutralizes 
toxic metabolites by condensing them enzymatically and non-enzymatically. GSH plays a 
major role in APAP detoxification since it spontaneously and rapidly reacts with the 
active toxic metabolite of the APAP (NAPQI) (k=3.2 ×104 M-1 s-1 at pH 7.0) or is 
catalyzed by glutathione S transferase  (GST).[83] An APAP overdose causes severe GSH 
depletion, allowing NAPQI to attach to protein (mainly mitochondrial protein), leading to 
oxidative stress, which ends in hepatocyte death. An i.v. administration of GSH after an 
APAP overdose results in accelerated recovery of the mitochondrial GSH content.[13] The 
elevated levels of mitochondrial GSH effectively scavenge reactive oxygen and 
peroxynitrite, which reduces APAP-induced liver injury and promotes regeneration. 
Glutathione-related enzymes, GPX and GR, that affect the conversion of GSSG to GSH 
(e.g., regeneration of GSH), are inhibited in the APAP-treated group, as well as other 
antioxidant enzymes (SOD, CAT, and GST) that play an important role in maintaining 
redox homeostasis under normal physiological conditions (Figure 2.8). This affects 
radical quenching capacity and results in oxidative stress.[21, 48, 70, 75] 
Lipid peroxidation shows when the antioxidant defense system fails to prevent 
excess formation of free radicals. It affects the physicochemical properties of membrane 
lipid bilayers, including decreases in membrane fluidity and inactivation of membrane 
bound enzymes that result in severe cellular dysfunction.[82] A lipid peroxidation chain 
reaction is initiated by a hydroxyl radical combining with one hydrogen from a 
methylene carbon on a polyunsaturated fatty acid (PUFA) to form water and a lipid 
radical. Due to the presence of many double bonds between carbon atoms, the abstraction 
of the hydrogen atom is easier and the resulting molecule is more stable. The lipid radical 
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is not a very stable molecule, so it reacts readily with molecular oxygen, thereby creating 
a peroxyl radical. This radical is also an unstable species that reacts with another free 
fatty acid, producing a different lipid radical that combines with the abstracted hydrogen 
to form hydroperoxides. This cycle continues, as the new fatty acid radical reacts in the 
same way. The lipid hydroperoxides decompose in the presence of metals, such as iron or 
copper, to form toxic aldehydes, such as 4-hydroxy-2-nonenal (4-HNE) and 
malondialdehyde (MDA). The APAP toxicity research community showed the role of 
lipid peroxidation in the aggravation of hepatic and renal toxicity.[20, 22, 33, 36, 63]  
 
 
Figure 2.6. Synthesis of glutathione (GSH) 
In step (1) ϒ-glutamylcysteine synthetase. (2) glutathione synthetase.  
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Figure 2.7. Structure of glutathione (GSH) on top, and glutathione disulfide (GSSG) at 




Figure 2.8. Antioxidant enzymes. 
2.4.3. Contributing Factors in Acetaminophen Toxicity. Factors that contribute 
to increased risk of APAP toxicity are generally due to one or both of the following two 
mechanisms: 
A) Depletion of GSH: as in the cases of malnutrition, eating disorders (such as 
anorexia nervosa), HIV infection, and cystic fibrosis.[84, 85] GSH is the first 
defensive line against the toxicity induced by APAP. NAPQI, which is the toxic 
metabolite of APAP, is detoxified by conjugation with GSH. [45-47] Therefore, a 
depleted GSH level, due to any disorder, means a defect in the defensive pool 
against toxicity, which increases the risk of toxicity. Several cases of 
hepatotoxicity have been reported from therapeutic doses of APAP when it is 
administered to fasting patients or to those who are not eating well.[84]  
B)  Induction of CYP: as in chronic alcohol use and use of drugs that induce an 
enzyme (mainly CYP2EA and CYP3A4 isoenzymes), such as phenytoin, 
barbiturate, and carbamazepine, that increase the risk of toxicity.[85] Inductions of 
CYP, that metabolizes APAP to the toxic metabolite (NAPQI), results in the 
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accumulation of NAPQI to levels that exceed the detoxification capacity of GSH. 
Genetic variations in CYP and APAP metabolism are documented, and it is well 
known that some patients are resistant to APAP toxicity.[86] 
       2.4.4. Role of Alcohol in Acetaminophen Toxicity. Chronic alcohol abuse is 
recorded in about 50% of the patients with APAP toxicity.[84] The underlying mechanism 
is related to the induction of CYP2E1,[87] and results in an increase in the production of 
NAPQI to a level that exceeds the availability of GSH for conjugation and detoxification. 
One reviewer suggested that the late presentation of those chronic alcohol patients was 
the main reason for the increased susceptibility to toxicity.[86] Although two of the largest 
published patient cases of APAP hepatotoxicity did not show a significant link between 
alcohol and APAP toxicity,[85] the FDA has required an alcohol warning on the label of 
all formulas containing APAP, by stating that patients should ask their doctor if they 
consume three or more alcoholic drinks per day.[84] 
Chronic alcoholism is often associated with poor nutrition (fasting state). Fasting 
affects APAP metabolism by decreasing the metabolism in the glucuronidation pathway, 
which enhances toxicity.[85] APAP is metabolized mainly to acetaminophen glucuronide 
(50% – 65% of APAP) by glucuronusyltransferase. Glucuronide is provided by uridine 
diphosphate-glucuronic acid (UDPG), which is derived from glucose 1-phosphate, that is 
derived from either glycogen or glucose 6-phosphate so that it is dependent on glucose 
reserves. There is a ten-fold difference in the glucose levels during a fasting state in rats 
than in the fed state, which is explained by the glucostat function of the liver. Liver 
metabolic pathways are directed to provide glucose to other organs by performing 
gluconeogenesis, thereby reducing the amount of glucose precursor available for 
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glucuronidation. The amount of the enzyme CYP, which increases directly by fasting (or 
because of diminished glucuronidation) is responsible for NAPQI (toxic metabolite) 
formation. At the same time, it decreases the availability of GSH, the precursor for 
NAPQI detoxification, which leads to the accumulation of NAPQI and results in 
toxicity.[88] Alcohol can potentiate the fasting effect on APAP toxicity by inducing 
CYP450 (mainly CYP2E1) as well (Figure 2.9).  
 
 
Figure 2.9. Role of alcohol and malnutrition in acetaminophen (APAP) toxicity 
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2.4.5. Prevention of Acetaminophen Toxicity. Responding to concerns about 
the high incidence of APAP toxicity, the FDA has announced many warnings over the 
years and has insisted that manufacturers adhere to various restrictions in their formulas 
to prevent and decrease further incidences of this toxicity. This intervention has included 
restricting tablet strength, limiting combination formulas, improving labeling and, most 
important, enhancing efforts for effective public education.[34] Unfortunately, some 
consumers believe that OTC products are extremely safe and are not likely to lead to 
serious toxicity. They do not read labels or follow directions for use. They are not aware 
that APAP can cause serious liver injury, and some people (e.g., certain users of alcohol 
and medications that induce CYP, and individuals with liver disease) may be more 
susceptible to hepatic injury. Because some patients may not get adequate pain relief after 
taking the recommended dosage of APAP, they may take more than the recommended 
amount, or use other products that also contain APAP. They should be aware that the 
symptoms of an APAP overdose may not appear for up to 3 days, so they may continue 
to take APAP and suffer increased damage. The symptoms of liver injury may mimic the 
condition that they are treating (e.g., flu symptoms). [89] 
2.5. TREATMENT OPTIONS FOR ACETAMINOPHEN TOXICITY 
2.5.1. Approved Option for Acetaminophen Toxicity Treatment (N-
acetylcysteine). 
 2.5.1.1. N-acetylcysteine mechanism of protection. N-acetylcysteine (NAC) is 
the drug of choice to treat APAP poisoning. The use of NAC in the treatment of APAP 
poisoning originated in England in the 1970’s. [90]  NAC helps reduce the effects of APAP 
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toxicity in different ways.[11-13] It functions to help replenish GSH stores and, in 
conjunction with NAPQI, acts as a detoxification agent for that toxic metabolite by 
providing an important GSH precursor, cysteine. The initial and rate-limiting step in GSH 
synthesis involves y-GCS that depends on cysteine availability. Although cysteine is 
normally available in low concentrations in the liver, its properties of rapid catabolism 
and poor solubility in aqueous media make direct administration of cysteine 
impossible.[17] Since depletion of GSH below a critical threshold concentration is 
required for APAP-induced toxicity, the main way that NAC helps protect against 
toxicity is by stimulating GSH synthesis. However, in order to provide effective 
protection by this method, the NAC has to be administered during the metabolism phase 
of APAP. NAC treatment accelerates the recovery of mitochondrial GSH and scavenges 
reactive oxygen and nitrogen species. Mitochondrial dysfunction is a consequence of 
oxidative stress induced by mitochondrial respiration inhibition and enhanced formation 
of reactive species into the mitochondrial (due to NAPQI binding to mitochondrial 
protein). This is the main step in APAP toxicity, so the mechanism of NAC helps reduce 
the toxicity and promotes regeneration.[11-13] NAC treatment, in addition to stimulating 
the synthesis of GSH, the body’s natural defense against endogenously generated reactive 
oxygen species and toxic acetaminophen metabolite (NAPQI), provides excess amino 
acids that are not needed for GSH synthesis as an energy substrate for the Krebs cycle to 
maintain a hepatic ATP level.[11-13]  
 2.5.1.2. N-acetylcysteine dosing and treatment protocol. The Food and Drug 
Administration (FDA) approved NAC for oral administration in 1985 (140 mg/kg by 
mouth or nasogastric tube diluted to 5% solution, followed by 70 mg//kg by mouth every 
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4 h for 17 doses) and intravenous (IV) administration in 2004 (loading dose is 150 mg/kg 
in 5% dextrose over 15 minutes; maintenance dose is 50 mg/kg, given over 4 h, followed 
by 100 mg/kg administered over 16 h). [91] Although oral and IV formulation are equally 
effective when administered 8-10 h after an APAP overdose, the IV route is preferred 
because of increased patient tolerance, a shorter treatment period, and cost 
effectiveness.[16]  
 APAP levels provide a basis for determining the need to initiate or continue 
treatment with NAC. These levels should be plotted in a nomogram and measured at 4 h, 
or as soon as possible [91] (Figure 2.10). Levels obtained before 4 h cannot be plotted in 
the nomogram.[91] In the UK, the standard treatment nomogram is called 200-line. It is 
drawn from an APAP concentration of 200 mg/L at 4 h to 30 mg/L at 15 h. 
Concentrations above the nomogram line are associated with a high risk of toxicity that 
indicates a requirement for NAC treatment.[92] If a patient is at high risk for toxicity due 
to other risk factors (malnutrition, chronic ethanol consumption, or taking any CYP 
inducer medication), then treatment should be more aggressive and follow a nomogram 
drawn at 50% of the standard treatment line (called 100-line). In the U.S. and Australia, a 
150-line is drawn intermediate to the UK standard, and high risk nomogram lines are 
used to determine the need for NAC treatment, while in Denmark, NAC is routinely 
administered to all patients after an APAP overdose, irrespective of the serum level of 
APAP.[17]  
            2.5.1.3. N-acetylcysteine drawbacks. The main drawbacks of NAC are the 
requirement for high doses and a long treatment course, due to poor bioavailability. Its 
carboxyl group loses its proton at physiological pH, making the compound negatively 
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charged, and making its passage through the biological membrane difficult.[14] High 
doses of NAC are associated with side effects such as occasional nausea, vomiting, rare 
urticaria, or bronchospasm (with oral administration), and it may also lead to an 
anaphylactic reaction with intravenous administration.[93, 94] The mechanism is related to a 
NAC concentration, that is dependent on histamine release, but it is different from the 
true anaphylaxis which is independent of tryptase and immunoglobulin E.[17] 
Discontinuing NAC administration, antihistamines, and epinephrine for bronchospasm 
may successfully treat these effects. Some studies have shown that prolonged use of NAC 
can delay liver recovery after APAP toxicity by impairing liver regeneration due to 
reduced NF-κB DNA binding and decreased expression of cyclin D1 protein in the liver 








Figure 2.10. Acetaminophen (APAP) nomogram      
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             2.5.2. Proposed Option for Acetaminophen Toxicity Treatment 
(N-acetylcysteine amide). N-acetylcysteine amide (NACA) is a modified form of NAC 
that has an amide group instead of a carboxyl group of NAC that increases its 
lipophilicity, allowing it to cross cell membrane easily [14] (Figure 2.11). NACA 
hydrolyzes to give cysteine, a precursor for GSH, which is the major component in 
defending against APAP toxicity. NACA has been shown to, not only overcome the 
drawbacks of NAC, but to have many advantages over it.[14] NACA is more membrane 
permeable than NAC and, owing to its neutral charge at the physiological pH, NAC is 
negatively charged at physiological pH that limits its ability to cross cell membranes and, 
therefore, requires higher doses and longer treatment times. The nausea and vomiting, 
caused when NAC is administered orally, and the anaphylactic reactions that follow its 
IV administration, could be overcome by using a lower dose of NACA, which has higher 
bioavailability, and eliminates the pro-oxidant effects of NAC that occur with higher 
concentrations.[14] The greater membrane permeability of NACA (over NAC) was 
addressed by Grinberg L et al. by using human red blood cells as a model system in a 
study where NACA was found to be five times more potent than NAC, suggesting better 
membrane permeability of NACA.[28] It acts as a carrier of NAC and acts directly as a 
free radical scavenger. The antioxidant and free radical scavenging abilities of NACA are 
equal to, or are an improvement over, those of NAC.[14] Ates et al. concluded from their 
study that amide derivatization had enhanced the antioxidant property of NAC.14 The 
authors also demonstrated in cell-free assays that the thiol-disulfide exchange between 
NACA and oxidized GSH (GSSG) was a mechanism of GSH regeneration.[28] 
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 Several studies have been undertaken to evaluate the effectiveness of NACA, as it 
can cross the blood brain barrier as well as biological membranes as an antioxidant and 
free radical scavenger, with promising results being reported.[95, 96] 
 
            
           NACA                                                                       NAC 
 
 
Figure 2.11. Chemical structures of N-acetylcysteine (NAC) and N-acetylcysteine amide 
                     (NACA)  
 
2.5.2.1. Application of N-acetylcysteine amide. Depletion of GSH renders cells 
particularly vulnerable to oxidative stress. The resulting damage is the key step in the 
onset and progression of many diseases. The protective effects of NACA as an 
antioxidant have been demonstrated both in vitro and in vivo using different cell lines and 
rodent animal models, respectively. I have summarized the role of NACA in various 
disorders, including neurotoxicity, hematological disorder, metal ion toxicity, radiation-






 2.5.2.1.1.1. Glutamate-induced toxicity. The protective effects of NACA and the 
mechanism behind its protection against glutamate-induced cytotoxicity in the neuronal 
cell line, PC12, were investigated.[97] Incubation of PC12 cells with glutamate resulted in 
reduction of GSH and cysteine levels, when compared to the control group. Reduced 
levels of cysteine indicated that the presence of excess glutamate inhibited cystine 
uptake, which led to decreased GSH levels. Depletion of intracellular GSH may also be 
due to glutamate-induced accumulation of ROS within the cell. NACA treatment was 
able to increase GSH and cysteine levels and to effectively reverse the inhibitory action 
of glutamate. It was demonstrated that NACA protects PC12 cells against glutamate-
induced cytotoxicity by preventing glutamate-induced loss of cellular GSH and inhibiting 
lipid peroxides. 
 2.5.2.1.1.2. Human immunodeficiency virus 1 (HIV-1)-associated 
neurotoxicity. The oxidative stress induced by HIV-1 proteins, gp120, and Tat, in vitro 
was studied in an immortalized cell line of rat brain endothelial RBE4 cells.[98] Exposure 
to gp120 and Tat proteins depleted intracellular GSH, enhanced MDA levels, and 
reduced CAT, GPx, and GR activities in cultured rat brain endothelial cells, indicating 
that HIV proteins induce oxidative stress in RBE4 cells. NACA treatment did reverse the 
increased caspase-3 activity following gp120 and Tat exposure. The oxidative stress 
induced by HIV-1 viral proteins was effectively blocked by NACA, and its effectiveness 
was further evaluated in an in vivo model.[99] Pretreatment of the animals (in the 
gp120+Tat+METH group) with NACA significantly increased the GSH levels, indicating 
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that the antioxidant NACA was able to partially abrogate oxidative stress-induced 
damage in these animals. 
2.5.2.1.1.3. Methamphetamine (METH) induced toxicity. The authors observed 
that METH causes oxidative stress to BBB cells, as demonstrated by decreased 
intracellular GSH, increased MDA levels, and intracellular ROS production, as well as 
decreased GPx activity.[31] In addition, METH treatment also alters the integrity of the 
BBB by increasing the permeability of the cells. These toxic effects of METH were 
reversed, however, by pretreatment of the cells with NACA. This antioxidant restored the 
levels of GSH, and scavenged the ROS produced by treatment with METH, thereby 
maintaining the permeability of the BBB.[100]  
2.5.2.1.2. Hematological disorder 
2.5.2.1.2.1. β-thalassemic patients. NACA, to a greater extent than NAC, 
effectively attenuated the oxidative stress on blood cells in vitro in β-thalassemic patients, 
as well as in vivo in mice.[101] It increased GSH and reduced ROS levels in RBCs, 
platelets, and polymorphonuclear leukocytes. In addition, NACA reduced RBC lysis and 
phagocytosis by macrophages more effectively than NAC did.  
2.5.2.1.3. Radiation-induced cytotoxicity. The search for more effective 
radioprotectors has intensified recently due to increased use of ionizing radiation in 
radiotherapy, for the treatment of malignant tumors, which induces oxidative damage to 
normal cells. The highly toxic hydroxyl radicals, produced by ionizing radiation, attacked 
the DNA molecules, causing single and double strand breaks. Additionally, the ROS also 
caused lipid peroxidation and protein oxidation. These deleterious changes negatively 
impacted cellular functions, resulting in cell death and, thereby, lowered cell viability. 
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NACA demonstrated better ability for preventing radiation-induced cytotoxicity and lipid 
peroxidation (as compared to NAC) in in vitro by using CHO cells.[102] Based on those 
results the authors concluded that NACA appears to be an ideal radioprotector. It offers 
good protection against radiation damage. 
2.5.2.1.4. Metal ion toxicity 
 
2.5.2.1.4.1. Lead. Lead is an ubiquitous environmental toxicant. Severe and acute 
lead poisoning can cause encephalopathy, convulsions, a coma, and even death. Despite 
several efforts to reduce lead levels in the environment, lead exposure continues to be a 
major public health problem, particularly in urban areas in the U.S., as well as in third 
world countries. Oxidative stress is possibly involved in lead toxicity. Lead crosses the 
BBB and accumulates in astrocytes, where it may impair cell function and perturb glial-
neuronal interactions. Therefore, antioxidants that cannot cross the BBB may not be 
effective against lead-induced neurotoxicity. NACA, which is able to cross the BBB, 
might be a potential therapeutic for use in treatment of lead-induced neurotoxicity. 
Furthermore, NACA was found to be more effective in lowering blood lead levels, when 
compared to NAC. This may be attributed to the greater permeability of NACA (than that 
of NAC). In addition, it was more effective than NAC at counteracting lead-induced 
hepatotoxicity. Considering current chelation therapy and the toxic effects of chelators, 
the authors suggest that NACA, which is multi-functional, may be effectively included in 
the treatment of lead poisoning.[103] 
2.5.2.1.4.2. Manganese. Manganese (Mn) is an essential trace element required 
for normal cellular functioning. However, overexposure of Mn can be neurotoxic, 
resulting in the development of manganism, a syndrome that resembles Parkinson's 
  
31
disease. Although the pathogenetic basis of this disorder is unclear, several studies have 
indicated that it is mainly associated with oxidative stress and mitochondrial energy 
failure. Pretreatment with NACA protects against Mn-induced toxicity by inhibiting lipid 
peroxidation, scavenging ROS, and preserving intracellular GSH and mitochondrial 
membrane potential.[104] 
2.5.2.1.5. Eye disorders. Cataracts, the most common cause of blindness 
worldwide, develop as a result of the progressive loss of transparency of the lens. It has 
been demonstrated that oxidative stress plays an important role in its pathogenesis. 
Supplemental NACA injections during L-buthionine-sulfoximine treatment (BSO, a GSH 
synthesis inhibitor that induces cataracts) were found to prevent cataract formation in 
most of the rat pups in the NACA+BSO group. NACA could confer a protective effect by 
providing a substrate for the generation of GSH and the ability to maintain antioxidant 
levels within the lens, possibly, through disulfide-exchange mechanisms.[105] Further, 
NACA has also been shown to ameliorate ter-butyl hydroperoxide (tBHP)-induced 
oxidative stress in retinal epithelial cells.[106]  
2.5.2.1.6. Medicinal drug-induced toxicity. The purpose of medicinal drugs is to 
cure certain diseases, or to relieve some symptoms. Unfortunately, many clinical 
medicinal drugs have some adverse effects, especially in cases of improper use and/or an 
overdose. Some of these are believed to have adverse effects by inducing oxidative stress. 
Therefore, antioxidants have been studied to determine if they alleviate the toxicity 
induced by these medicinal drugs. 
2.5.2.1.6.1. Bleomycin-induced oxidative stress. Bleomycin (BLM), a 
glycopeptide antibiotic from Streptomyces verticillus, is an effective antineoplastic drug. 
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However, its clinical use is restricted due to a wide range of associated toxicities, 
especially pulmonary toxicity. Oxidative stress has been implicated as an important factor 
in the development of BLM-induced pulmonary toxicity. NACA was determined to have 
a protective role against BLM-induced toxicity by inhibiting lipid peroxidation, 
scavenging ROS, and preserving intracellular GSH and mitochondrial membrane 
potential by using the A549 cell as a cell model.[30] 
2.5.2.1.6.2. Nitrofurantoin-induced oxidative stress. Nitrofurantoin (NFT) is an 
antibiotic that is commonly used for treatment of urinary tract infection and other 
infections caused by Gram-negative bacteria (such as E. coli). However, it is 
contraindicated in oxidation-sensitive patients with glucose-6-phosphate (G-6-PD) 
deficiency or related genetic disorders due to the risk of intravascular hemolysis. It is 
well known that NFT causes oxidative stress by generating superoxide anion via a redox 
cycle that occurs in the liver. Results indicate that NFT causes oxidative stress in this cell 
line (HepaRG) and NACA protects cells from this oxidative damage (data not published). 
2.5.2.1.6.3. Doxorubicin-induced oxidative stress. Doxorubicin is a potent and 
broad-spectrum antineoplastic agent. However, its lengthy treatment term may be 
associated with irreversible cardiomyopathic changes and consequent congestive heart 
failure. The cardiotoxicity is believed to be caused by oxidative stress.[107] The generation 
of free radicals may lead to dysfunction of the mitochondria in cardiac cells, interference 
with cell calcium regulation, and bioenergetics failure. NACA shows a protective effect 
against its toxicity by using H9c2 cardiomyocytes. NACA reduces the level of lipid 
peroxidation, ROS, and increases both GSH and GSH/GSSG ratio levels. It restores the 
antioxidant enzymes levels as well.[108] 
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2.5.2.1.6.4. Iohexol-induced oxidative stress. Iohexol is one of the most widely 
used contrast agent. Usage of radiocontrast media in radiological procedures has been 
reported to cause contrast-induced nephropathy via a poorly understood mechanism. 
However, oxidative stress has been proposed as one of the possible mechanisms. NACA 
shows a protective effect against apoptosis of renal proximal tubular epithelial cells, 


















3. EXPERIMENTAL DESIGN 
The experiments were performed with male C57BL/6 mice (Charles River 
laboratories), that were 7 to 9 weeks old, were housed in an environmentally controlled 
room with a 12 h light/dark cycle, and allowed free access to food and tap water. The 
animals were acclimatized for a minimum of 1 week before the experiment and drugs 
were administered i.p. at the indicated dose in phosphate buffered saline (PBS). 
The effects of NACA as an antidote for APAP toxicity were determined by two 
different experiments. The potential for antidote activity was the focus of Experiment 1 
and the protective effects of NACA in APAP-induced oxidative organ injury were 
evaluated in Experiment 2 by measuring numerous oxidative stress parameters (detailed 
below). The proposed mechanism of protection of NACA is shown in Figure 3.1. 
  
3.1. EXPERIMENT 1: EXPERIMENTAL DESIGN FOR SURVIVAL STUDY 
 
The animals were divided into four groups (n=40) as PBS, APAP, APAP+NAC, 
and APAP+NACA. NAC or NACA (106 mg/kg) was administered 1.5 h post to APAP 
administration (500 mg/kg) and then every 12 h for 72 h. The animals were monitored for 
a week and body weight was recorded every day. ( Table 3.1) 
Table 3.1. Experimental design for survival study 
Group 
(n=10) 
Treatment (all in i.p) 
Control PBS 
APAP APAP (500 mg/kg) 
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Table 3.1. Experimental design for survival study (cont.) 
 
APAP+ NAC APAP (500 mg/kg) then after 1.5 h NAC (106 mg/kg) and repeat NAC 
dosing q12 h for 72 h 
APAP+ 
NACA 
APAP (500 mg/kg) then after 1.5 h NACA (106 mg/kg) and repeat 
NACA dosing q12 h for 72 h 
 
3.2. EXPERIMENT 2: EXPERIMENTAL DESIGN FOR OXIDATIVE STRESS 
  STUDIES 
 
The protective effects of NACA in APAP-induced oxidative organ injury were 
performed with the animals being divided into six groups (n=36) as PBS, NAC, NACA, 
APAP, APAP+NAC, and APAP+NACA (Table 3.2). Food was withdrawn 12-15 h prior 
to treatment.  NAC or NACA (106 mg/kg) was administered 1.5 h post to APAP 
administration (300 or 400 mg/kg) and the mice were sacrificed 4 or 24 h after APAP 
injection; blood was then drawn and centrifuged to obtain serum. Liver, kidney, brain, 
and spleen samples were removed and a portion from each lobe of the liver was fixed in 
10% phosphate-buffered formalin for histology or kept in a mitochondrial isolation buffer 
to isolate the mitochondria. The rest of the livers, kidneys, brains, and spleens were 
immediately frozen on liquid nitrogen and kept at -80°C until analysis. 
As the toxicity of APAP is dose-and-time dependent, according to results 
published previously based on using cell and animal models, we studied this toxicity by 
using two different doses of APAP (300 and 400 mg/kg) for 4 h treatment periods. We 
evaluated this toxicity at two different time points (4 h and 24 h), as well as by using a 
fixed dose (300 mg/kg). The effects of NAC and NACA on the toxicity induced by 
different doses of APAP and different treatment times were evaluated by conducting 
some of the experiments mentioned in chapter 4.   
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Group (n=6) Treatment (NAC and NACA will be 
given 1.5 h later than PBS or APAP, 
all in i.p.) 
Control PBS 
NAC only PBS + NAC (106 mg/kg) 
NACA only PBS + NACA (106 mg/kg) 
APAP only PBS + APAP 
APAP+NAC APAP + NAC (106 mg/kg) 





                                                                                                                                      
Figure 3.1. Proposed mechanism of protection of N-acetylcysteine amide (NACA) 
In 1: NACA provides cysteine that helps in GSH synthesis; 2 and 4: NACA scavenges 
the reactive oxygen species; 3: NACA provides excess cysteine as energy substrate for 

















































4.1. HPLC METHODS 
       4.1.1. Intracellular Glutathione (GSH). Intracellular GSH content was determined 
by reverse phase HPLC, according to the method developed in our laboratory.[110] The 
samples were homogenized in serine borate buffer (SBB).  Fifty microliters of this 
homogenate were added to 200 µl of HPLC grade water and 750 µl of NPM (1 mM in 
acetonitrile).  The resulting solutions were incubated at room temperature for 5 min.  The 
reaction was stopped by adding 10 µl of 2 N HCl.  The samples were then filtered 
through a 0.45 µm filter (Advantec MFS, Inc. Dulin, CA, USA) and injected onto the 
HPLC system (Figure 4.1).  5 µl of the sample were injected for analysis using a Thermo 
Finnigan TM Spectra SYSTEM SCM1000 Vacuum Membrane Degasser, Finnigan TM 
SpectraSYSTEM P2000 Gradient Pump, Finnigan TM SpectraSYSTEM AS3000 
Autosampler, and FinniganTM SpectraSYSTEM FL3000 Fluorescence Detector 
(λex=330 nm and λem=376 nm).  The HPLC column was a Reliasil ODS-1 C18 column 
(Column Engineering, Ontario, CA, USA).  The mobile phase was 70% acetonitrile and 
30% water and was adjusted to a pH of 2.5 through the addition of 1 ml/L of both acetic 
and o-phosphoric acids.  The NPM derivatives were eluted from the column isocratically 
at a flow rate of 1 ml/min; an example of the chromatogram is shown in Figure 4.2.  
       4.1.2. Total Glutathione (GSH) and Glutathione Disulfide (GSSG). Total 
glutathione content was determined by reverse phase HPLC. Samples were homogenized 
in SBB.  Fifty microliters of this homogenate were added to 60 µl of NADPH (2 mg/ml) 
in nanopure water and 20 μl of 1 unit/ml glutathione reductase were added to reduce 
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GSSG. After 3 min of incubation at room temperature, the treated samples were diluted 
with 120 μl H2O, and then immediately derivatized with 750 μl of 1.0 mM NPM. These 
samples were analyzed as detailed for the determination of GSH using reverse phase 
HPLC. Data from the original GSH levels and the total GSH levels in each sample were 
subsequently used to calculate the levels of GSSG present in each sample. 
 









Figure 4.1. Reaction of (1-pyrenyl) maleimide (NPM) with SH group to produce 
fluorescent thiol derivative 
 
 















       4.1.3. Lipid Peroxidation. Malondialdehyde (MDA) is a thiobarbituric acid reactive 
substance. The extent of lipid peroxidation was determined as described by Shi et al.[108] 
Briefly, the samples were homogenized in SBB.  To 0.350 ml of the homogenate, 0.550 
ml of 10% trichloroacetic acid (TCA) and 0.100 ml of 500-ppm butylated 
hydroxytoluene (BHT) in methanol were added.  The samples were then heated in a 
boiling water bath for 30 min.  After cooling on ice, the samples were centrifuged.  The 
supernatant fractions were mixed 1:1 with saturated thiobarbituric acid (TBA).  The 
samples were again heated in a boiling water bath for 30 min.  After cooling on ice, 0.50 
ml of each sample was extracted with 1 ml of n-butanol and centrifuged to facilitate the 
separation phases.  The resulting organic layers were first filtered through a 0.45 µm 
filter and transferred to HPLC vials for analysis. Fluorescence was then measured (ex. 
515 nm and em. 550 nm). (Figure 4.3.) 
Figure 4.3. The reaction of malondialdehyde (MDA) with thiobarbituric acid (TBA) to 
                   form MDA-TBA fluorescent adduct 
 
 
       4.1.4. Depletion of thiol antioxidants by NAPQI. Cell-free experiments were 
performed to determine the effect of NAPQI on GSH, NAC, and NACA levels. This was 
assayed by comparison of GSH, NAC, and NACA levels in the presence and absence of 

























unbound thiol levels. 5 µM aqueous solutions of GSH, NAC and NACA (triplicates of 
each) were prepared. This group served as a control. Then, identical solutions were 
prepared, except NAPQI was added to each for a final concentration of 10 µM NAPQI. 
Both sets were incubated for 30 minutes at room temperature. Then, each was derivatized 
with NPM, which reacts with only free sulfhydryl groups to form fluorescent derivatives.  
 
4.2.SPECTROPHOTOMETRIC METHODS 
       4.2.1. Serum Alanine Aminotransferase (ALT). To get the serum, blood was first 
allowed to clot for 30 min at room temperature, and then it was centrifuged at 2000 ×g 
for 15 minutes at 4°C. The top yellow serum layer was pipetted off without disturbing the 
white buffy layer. ALT was measured (using a kit-Cayman Chemical) by adding 150 ul 
of substrate, 20 ul of cofactor, and 20 ul of sample in a 96-well plate, and incubating at 
37°C. After15 min, reactions were initiated by adding 20 ul of ATP initiator and 
immediately reading the plate at 340 nm, once every min for 5 min (Figure 4.4.) 
 
Figure 4.4. The activity of alanine transaminase (ALT). 
       4.2.2. Glutamate Dehydrogenase (GDH). GDH was determined as described by 
McGill et al. [46] Briefly, aliquots with 10–100 μl of serum were mixed in 700 μl of 200 
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mM imidazole buffer with 25 mM of ammonium acetate, 200 μM of NADH, 100 μM of 
ADP, and 0.05% bovine serum albumin, pH 8.0. The disappearance of NADH was 
monitored at 340 nm to obtain a baseline reading, and then 50 μl of a 2 mM α-
ketoglutarate solution were added to begin the GDH reaction. The baseline activity was 




Figure 4.5. Activity of glutamate dehydrogenase enzyme (GDH) 
 
       4.2.3. Glutathione Reductase (GR) Activity. GR is the enzyme responsible for 
recycling GSSG into GSH via a reduction mechanism, utilizing both GSSG and NADPH 
as a substrate. The oxidation of NADPH to NADP+ is accompanied by a decrease in 
absorbance at 340 nm, providing a spectrophotometric means for monitoring the enzyme 
activity of GR. The activity of GR is determined by adding homogenate to a solution 
containing both GSSG and NADPH, and then recording the absorbance as a function of 
time at 340 nm. The rate of decrease in the A340 is directly proportional to the GR 















Figure 4.6. Activity of glutathione reductase enzyme (GR) 
 
       4.2.4. Creatine Kinase (CK) Activity. Creatine kinase activity was determined in 
the serum by using a kit (Pointe scientific Inc.) and by initially preparing the working 
reagent by mixing five parts of R1 with one part of R2. Then, 1 ml of this reagent mix 
was pipetted into an appropriate tube and pre-warmed at 37°C for 5 min. 25 ul of a 
sample were transferred to this reagent, mixed, and incubated at 37°C for 2 min. A 
reading was recorded after 2 min after the spectrophotometer was zeroed with water at 
340 nm. The sample tube was returned to 37°C and a reading was repeated every min for 
2 min. (Figure 4.7.) 
 




       4.2.5. Blood Urea Nitrogen Level (BUN). BUN level was determined in the serum 
by using a kit (Pointe scientific Inc.). The procedure was started by preparing a working 
reagent by mixing five parts of R1 with one part of R2. Then, 1 ml of this reagent mix 
was pipetted into an appropriate tube and pre-warmed at 37°C. After that, 10 ul of 
calibrator, control, or sample were added to the tube and immediately placed in the 
spectrophotometer. The rereading was recorded after 30 sec and then after 60 sec (the 
spectrophotometer was zeroed with water at 340 nm).  
       4.2.6. Protein Determination. Protein levels of the samples were measured by the 
Bradford method.[111] Concentrated Coomassie blue was diluted 1:5 with HPLC water. 20 
ul of the sample or standard were then added to 1 ml of this diluted dye, the solution was 
then vortexed, and allowed to stand at room temperature for 5 min. The absorbance was 
then measured at 595 nm by using a UV spectrophotometer.  Bovine serum albumin was 
used as the protein standard. 
 
4.3.ISOLATION OF MITOCHONDRIA 
   Liver samples were homogenized in a mitochondrial isolation buffer (215 mM of 
Mannitol, 75 mM of Sucrose, 0.1 % BSA, 1 mM of EGTA, and 20 mM of HEPES). The 
samples were spun at 1,300 g for 3 min at 4º. Supernatant was poured into a new tube and 
spun at 13,000 g for 10 min. The pellets were re-suspended in 10% v/v DMSO/Isolation 
buffer and saved in a temperature of -80°C until analysis.[112] 
 
4.4. HISTOLOGY 
   Formalin fixed liver samples were embedded in paraffin and 5-µm sections                       
were cut.  Replicate sections were stained with Hematoxylin and Eosin (H&E) and 
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evaluated by a pathologist in a blind study. Three liver sections with five fields of 20X 
view were evaluated for hemorrhage, hepatocellular vacuolization, and hepatocellular 
necrosis, scored from 0 (no change) to 4 (severe change). These values were used to 
determine a total lesion score for each animal, scaled from 0 (no change) to 16 (severe 
change). The number of liver samples was three per treatment group. 
 
4.5. STATISTICAL ANALYSIS 
   All reported values were represented as the mean ± S.D. (n=3-6). Statistical 
analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA). 
Statistical significance was ascertained by one-way analysis of variance, followed by 
Tukey’s multiple comparison tests. Values of p<0.05 were considered significant. 
Survival data were analyzed using the Kaplan-Meier method, and the log-rank test was 














5. SURVIVAL STUDY 
5.1. RESULTS 
 5.1.1. Potential Antidotal Effect of N-acetylcysteine or N-acetylcysteine amide 
in Acetaminophen Intoxicated Animals (Survival Study). APAP dosing decreased the 
survival percentage to 30% (as compared with 100% for the control) after 4 days of 
APAP intoxication, and maintained that percentage until the end of the week. Post 
treatment with NACA increased the survival to 100%, which was the same as that of the 
control group for the entire period. However, NAC was not as effective as NACA 
because it increased the survival rate to only 60% of the control by the end of the 
observation period (Figure 5.1). There was a significant increase in liver GSH in all of 
the treated groups, following the survival observation period. It had dramatically 
increased in the APAP-only treated group and less in the NAC-treated group, with the 
least in the NACA-treated group (which was closest to that of the control), as shown in 
Figure 5.2.  
 5.1.2. The Effect of N-acetylcysteine or N –acetylcysteine amide on the 
Weight of the Animals Intoxicated with Acetaminophen. Individual body weights of 
all treatment groups were compared during the observation period. These weights showed 
significant decreases in the APAP-treated group, and post treatment with NAC did not 
help. NACA treatment, however, was able to increase the body weights to levels that 




Figure 5.1. Survival curve for APAP toxicity for a period of one week 
C57BL/6 mice were intoxicated by a lethal dose of APAP (500 mg/kg), followed by 
NAC/NACA (106 mg/kg) at 1.5 h post APAP, and then every 12 h up to 72 h (n=10). 
Circle represents control group, square represents APAP group, triangle represents 
APAP+ NAC group, and inverted triangle represents APAP+ NACA group. A significant 
difference (p= 0.0291) was observed between the APAP+NAC group and the 





































Figure 5.2. Liver glutathione level (GSH) 18 days post acetaminophen (APAP) injection 
GSH level of liver sample of animals who lived after the observation period of the 
survival study in which C57BL/6 mice were intoxicated by a lethal dose of APAP (500 
mg/kg), followed by NAC/NACA (106 mg/kg) at 1.5 h post APAP, and then every 12 h 
up to 72 h. Control (n=10), APAP (n=3), APAP+NAC (n=6), and APAP+NACA (n=10). 
Values represent mean ±SD (n=6) (*: different from the control group, #: different from 









Figure 5.3. The effect of N-acetylcysteine or N-acetylcysteine amide on the weight of 
mice injected by APAP for a week 
C57BL/6 mice were intoxicated by a lethal dose of APAP (500 mg/kg), followed by 
NAC/NACA (106 mg/kg) at 1.5 h post APAP, and then every 12 h up to 72 h (n=10). 
Circle represents control group, square represents APAP group, triangle represents 


























An APAP overdose leads to the damage of various organs (mainly the liver and a 
second organ, the kidney), which results in high mortality rates, as reported in studies by 
many investigators.[113-117] The rescue potential of NAC and NACA was studied by 
conducting a survival study and weight monitoring. NAC is the only known antidote for 
APAP toxicity on the market today. In this study, mortality was not observed until 48 h 
after APAP dosing, mainly because of the nutritional status of the animals since they 
were fed before dosing with APAP. Fasting is known to deplete GSH and, therefore, the 
hepatotoxicity induced by APAP increases, which also increases the mortality rate. This 
result is consistent with other reported results that were conducted under the same 
conditions.[118] After 48 h, we observed a significant decrease in the survival percentage 
of the APAP-treated group, which had reduced to about 30% by the end of the 
observation period. NACA was better than NAC at increasing the survival percentage to 
coincide with that of the control group. The drastic increase in the liver GSH of the mice 
in the APAP-treated group, that were alive at the end of the study, indicated that the 
defending mechanism of the liver had overcome the toxicity by regenerating GSH. The 
drastic increase in GSH in the APAP-treated group (when the body was trying to 
overcome toxicity by producing more GSH) is a natural defense mechanism of the body. 
In the NAC-treated group, the increase in GSH was less than that in the APAP-only 
treated group, while that in the NACA-treated group was even less and was close to the 
control level, indicating less toxicity in this group. 
  Many researchers reported losses in body weight that were caused by an 
overdose of APAP.[119, 120] Adjuwon et al.[119] explained these weight loses by relating 
them to suppression of appetite and subsequent increases in the metabolic state associated 
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with hypoglycemia, which is associated with APAP-induced hepatotoxicity. Literature 
review showed metabolic complications of an APAP overdose that included 
hypoglycemia. Adeneye A. et al.[66] related the weight loss in their study to the greater 
urinary volume recorded in the APAP-treated group that indicated renal lesion and 
nephrotoxicity, which is explained in detail in chapter 7. NACA was able to maintain 
animal weights and survival percentages at values similar to those of the control. 
APAP intoxication led to multi-system failure in the mice (discussed in detail in 
chapters 6, 7, and 8), leading to attenuation in the weights of the mice and increases in the 
mortality percentages.  NACA was able to rescue the mice and maintain their survival 
percentages on a par with those of the control group. These results indicated that NACA 















   6.1.1 Effect of NAC/NACA on Intracellular Levels of GSH, GSSG, and 
GSH/GSSG. As depletion of intracellular GSH is a first step in APAP-induced toxicity, 
we studied the effect of APAP on GSH levels. An APAP overdose caused a dose-
dependent toxicity. I studied APAP-induced toxicity at two different doses of APAP: 300 
mg/kg and 400 mg/kg. Furthermore, I chose to study toxicity at two different time points 
for the 300 mg/kg dose of APAP to gain further insight into the regeneration mechanism 
of GSH as reported in literature. The GSH level reduced to 25% of the control with the 
dosing of 300 mg/kg APAP at 4 h post APAP injection (Figure 6.1 A). However, there 
was no significant change in the level of GSSG at this dose and time point (Figure 6.1 B). 
The GSH/GSSG ratio decreased to around 60% of the control, which is a better indicator 
of oxidative stress (Figure 6.1 C). Furthermore, treatment with NACA resulted in a 
significant increase in the GSH level, along with a significant decrease in the level of 
GSSG. However, NAC was not effective at restoring these levels. 
A 24-h treatment time with 300 mg/kg of APAP did not cause any change in the 
GSH level (Figure 6.2 A), but the GSSG level increased by about two fold compared to 
that of the control (Figure 6.2 B). This elevation in the GSSG level resulted in a 
considerable reduction in the GSH/GSSG ratio to around 62% of the control level (Figure 
6.2 C). Interestingly, NAC and NACA were equally effective at decreasing the GSSG 




To study the effect of a dose of APAP on toxicity, I studied the oxidative stress 
parameters at 4 h post of an APAP dose of 400 mg/kg as well. The results indicated that 
GSH levels decrease significantly to approximately 22% of the control after treatment 
with 400 mg/kg at 4 h post of an APAP dose (Figure 6.3A), with a concomitant increase 
in the levels of GSSG (oxidized form of GSH; Figure 6.3 B). Although the decrease in 
GSH, with a 400 mg/kg dose of APAP, is comparable to that with a 300 mg/kg dose of 
APAP, there is an increase in GSSG with the 400 mg/kg dose, which leads to a further 
reduction in the GSH/GSSG ratio to 16% of control (Figure 6.3 C). However, the 300 
mg/kg APAP dose leads to a GSH/GSSG ratio of 60% of control. Interestingly, the 
treatment with NAC was not effective at increasing the level of GSH or the GSH/GSSG 
ratio and significantly decreasing the level of GSSG. However, the NACA-treatment 
group showed a significant increase in the GSH level (approximately 66.5% of the 
control), in addition to a significant decrease in GSSG, leading to a considerable increase 
in the ratio of GSH/GSSG (60.5% of the control). Since significant toxicity was observed 
with a 400 mg/kg dose of APAP, I chose this dose and time point for further studies. 
6.1.2 Effect of NAC/NACA on Mitochondrial Levels of GSH, GSSG, and 
GSH/GSSG. An APAP dose of 400 mg/kg led to a significant reduction in mitochondrial 
GSH (Figure 6.4 A) at 4 h post APAP injection with no change in the GSSG level (Figure 
6.4 B). The ratio of GSH/GSSG was reduced to around 4% of the control (Figure 6.4 C). 
NACA treatment was successful in restoring GSH levels and the GSH/GSSG ratio to 
around 87% and 78% of the control, respectively. However, NAC was not able to restore 




6.1.3 Depletion of thiol antioxidants by NAPQI. Many investigators have 
pointed to the formation of the GSH-NAPQI conjugate as the critical step in 
detoxification of NAPQI at therapeutic doses of APAP. A cell-free experiment was 
performed to determine whether excessive amounts of NAPQI could be bound in the 
presence of sufficient quantities of GSH or another thiol antioxidant. The proportion of 
the unbound NACA was determined to be significantly different from the unbound NAC 
and unbound GSH (p<0.01) (Figure 6.5). This suggests that in the presence of NAPQI, a 
higher proportion of NACA reacts with NAPQI, compared to the other thiols. 
6.1.4 Effect of NAC/NACA on the Activity of GR. GR activity was reduced to 
57% of the control after 400 mg/kg of APAP treatment for 4 h. NACA treatment restored 
the GR activity to a level that was not very different from that of the control, while NAC 
was not able to significantly increase the activity of GR (Figure 6.6 A). 
Administration of 300 mg/kg of APAP for 4 h reduced the level of GR enzyme to 
84.5% of the control, and neither NAC nor NACA was not be able to restore this level 
back to the control level (Figure 6.6 B). However, a 24-h treatment period of 300 mg/kg 
APAP dosing increased the GR level to 54% of the control. Post treatment with NAC or 
NACA had the same effect by reducing the level back to that of the control (Figure 6.6 
C).  
6.1.5 Protective Effect of NAC/NACA on Lipid Peroxidation. MDA, an index 
of lipid peroxidation, increased significantly after treatment with 400 mg/kg of APAP 
and with 300 mg/kg of APAP by 145% or 70% of the control, respectively, at 4 h post 
APAP injection. Increasing the dose of APAP resulted in increased MDA levels. NAC 
was effective at decreasing the level of MDA; however, it was not very different from the 
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control or the APAP group. Furthermore, NACA was better than NAC at decreasing the 
MDA levels significantly when compared with the APAP treated group (Figures 6.7 A 
and B). MDA levels were elevated in the APAP group (53% higher than control) at 24 h 
post a 300 mg/kg dose of APAP. However, NAC and NACA acted equally to reduce this 
elevation close to control (Figure 6.7 C). 
6.1.6 Protective Effect of NAC/NACA on ALT Activity. Activity of ALT, a 
liver function enzyme, which was measured in the serum at 4 h post APAP treatment 
(400 mg/kg), showed a 100-fold increase over that of the control level. Treatment with 
NACA significantly reduced this increase in ALT activity to about 70% of that of the 
APAP-treated group, while NAC treatment did not reduce it significantly (Table 6.1 A). 
An APAP dose of 300 mg/kg resulted in a 10-fold increase in ALT activity 
compared to that of the control at 4 h post APAP dose. Both NAC and NACA were able 
to reduce this elevation significantly, but NACA was better than NAC at reducing it 
(Table 6.1B). However, at 24 h post, an APAP dose of 300 mg/kg led to around a 2.5-
fold elevation in ALT activity. NAC and NACA acted equally to greatly reduce this 
elevation (Table 6.1 C). 
6.1.7 Protective Effect of NAC/NACA on GDH Activity. GDH activity 
increased 25-fold from that of the control, after APAP treatment (400 mg/kg for 4 h). 
NACA treatment, however, significantly reduced the GDH activity to 15 times that of the 
control group, while NAC was unable to significantly reduce the activity (Table 6.1 A). 
An APAP dose of 300 mg/kg for 4 h resulted in an increase in GDH activity to 
approximately six times the activity of the control. Both NAC and NACA were able to 
reduce this elevation significantly, but NACA was better than NAC at reducing it (Table 
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6.1B). While APAP dosing for 24 h led to around a four-fold elevation of GDH, both 
NAC and NACA were able to reduce the levels considerably (Table 6.1 C). 
6.1.8 Effect of NAC/NACA on Protecting Liver Tissue (Macroscopic and 
Microscopic Evaluation). It has been previously shown that APAP toxicity can induce 
centrilobular necrosis. This is widely thought to be due to the abundant distribution of 
CYP in this region, which is responsible for APAP metabolism.[121] In this study, mice 
treated with APAP (400 mg/kg) had small, multifocal pale areas of tissue necrosis 
throughout all lobes of their livers, while the livers of control mice and those in the 
APAP+NACA group looked grossly normal (Figure 6.8). Histologically, liver sections 
from mice in the control group treated with PBS were within normal limits and 
hepatocellular damage was not observed (Figure 6.9 A, 6.10 A, and 6.11 A).  However, 
liver sections from mice in the APAP-treated group (400 mg/kg) showed severe diffuse 
coagulative necrosis around the central veins (Figure 6.9 B). Necrotic areas were 
characterized by swollen, vacuolated, eosinophilic hepatocytes consistent with previously 
described APAP toxicity.[24, 122] Liver sections from mice in the APAP+NAC treated 
group had mild, centrilobular to midzonal hepatocellular changes characterized by one to 
two medium sized vacuoles to clusters of several small vacuoles (Figure 6.9 C arrows) 
with rare clusters of one to three infiltrating mononuclear cells.  In contrast, mice in the 
APAP+NACA group had only occasional multifocal, centrilobular to midzonal areas of 
mild hepatocellular vacuolization characterized by clusters of several small vacuoles 
(Figure 6.9 D arrow heads).  Necrosis and hemorrhage were not observed in either the 
APAP+NAC or APAP+NACA groups. Liver sections of mice treated with 300 mg/kg 
APAP for 4h did not show any necrosis (Figure 6.10 B), while the 24h treatment showed  
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mild necrosis (Figure 6.11 B). NAC or NACA treated liver sections in both treatment 
groups were within normal limits and hepatocellular damage was not observed (Figure 
6.10 and Figure 6.11 C and D). To quantitatively assess hepatocellular damage, five 20X 
fields of view of three histologic sections of liver per mouse were scored for severity of 
hemorrhage, hepatocellular vacuolization, and hepatocellular necrosis and a total lesion 
score, ranging from 0 (no damage) to 16 (severe damage), for each mouse was 
determined.  Hepatocellular damage for the APAP (400 mg/kg at 4h), was the most 
severe and was statistically different from the PBS, APAP+NAC and APAP+NACA 
treated groups. However, 300 mg/kg treatment of APAP for 4h and 24h was not able to 
induce hepatocellular damage statistically different from the control. No statistical 
differences were found between the PBS or APAP+NAC and APAP+NACA treated  













Figure 6.1. Liver glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG ratio 
levels of C57BL/6 mice injected 
with APAP (300 mg/kg) for 4 h 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio. Post treatment 
with NAC or NACA (106 
mg/kg) at 1.5 h after APAP 
treatment in all treatment groups. 
Values represent mean ±SD 
(n=6) (*: different from the 
control group, #: different from 
the APAP group, and ^: different 

































































































































































Figure 6.2. Liver glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG 
ratio levels of C57BL/6 mice 
injected with APAP (300 
mg/kg) for 24 h 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio. Post 
treatment with NAC or 
NACA (106 mg/kg) at 1.5 h 
after APAP treatment in all 
treatment groups. Values 
represent mean ±SD (n=6) 
(*: different from the control 
group, #: different from the 
APAP group, and ^: different 





































































































































































Figure 6.3. Liver glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG ratio 
levels of C57BL/6 mice injected 
with APAP (400 mg/kg) for 4 h 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio. Post 
treatment with NAC or NACA 
(106 mg/kg) at 1.5 h after APAP 
treatment in all treatment 
groups. Values represent mean 
±SD (n=6) (*: different from the 
control group, #: different from 
the APAP group, and ^: 










     
 
     


































































































































































Figure 6.4. Liver’s 
mitochondrial glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG 
ratio levels of C57BL/6 mice 
injected with APAP (400 
mg/kg) for 4 h 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio. Post 
treatment with NAC or 
NACA (106 mg/kg) at 1.5 h 
after APAP treatment in all 
treatment groups. Values 
represent mean ±SD (n=6) (*: 
different from the control 
group, #: different from the 
APAP group, and ^: different 





Figure 6.5. Depletion of thiol antioxidants by NAPQI. 
 
Cell-free experiment in which 5 µM aqueous solutions of GSH, NAC and NACA 
(triplicates of each) were prepared. The decrease in levels of the given thiol after addition 
of 10 µM NAPQI suggest the formation of NAPQI conjugates, and therefore greater 
detoxification capacity.  Our results indicate NACA levels dropped more than GSH or 
































































































































































Figure 6.6. Liver 
glutathione reductase (GR) 
activity 
 
C57BL/6 mice injected 
with (A) APAP (400 
mg/kg) for 4 h, (B) APAP 
(300 mg/kg) for 4 h, and 
(C) APAP (300 mg/kg) for 
24 h. Post treatment with 
NAC or NACA (106 
mg/kg) at 1.5 h after APAP 
treatment in all treatment 
groups. Values represent 
mean ±SD (n=6) (*: 
different from the control 
group, #: different from the 
APAP group, and ^: 
different from APAP+ 























































































































































































C57BL/6 mice injected with 
(A) APAP (400 mg/kg) for 
4 h, (B) APAP (300 mg/kg) 
for 4 h, and (C) APAP (300 
mg/kg) for 24 h. Post 
treatment with NAC or 
NACA (106 mg/kg) at 1.5 h 
after APAP treatment in all 
treatment groups. Values 
represent mean ±SD (n=6) 
(*: different from the 
control group, #: different 
from the APAP group, and 
^: different from APAP+ 




Table 6.1. Serum levels of alanine aminotransferase (ALT) and glutamate dehydrogenase 
(GDH) 
 
C57BL/6 mice injected with (A) APAP (400 mg/kg) for 4 h, (B) APAP (300mg/kg) for 4 
h, and (C) APAP (300 mg/kg) for 24 h. Post treatment with NAC or NACA (106 mg/kg) 
at 1.5 h after APAP treatment in all treatment groups. Values represent mean ±SD (n=6) 
(*: different from the control group, #: different from the APAP group, and ^: different 
from APAP+ NAC group) p<0.05. 
 
  Control APAP APAP+NAC APAP + NACA 
A ALT 0.010±0.004 0.939±0.130* 0.857±0.126* 0.704±0.139*# 
GDH 6.906±2.181 169.7±35.44* 138.3±17.61* 105.7±6.240*# 
B ALT 0.017±0.005 0.112±0.021* 0.078±0.016*# 0.040±0.009*# 
GDH 6.590±1.789 38.63±3.453* 31.94±2.994*# 21.35±1.863*#^ 
C ALT 0.021±0.006 0.056±0.023* 0.016±0.002# 0.013±0.002# 











Figure 6.8. Macroscopic assessment of liver lobes from untreated and treated C57BL/6 
mice with APAP (400 mg/kg for 4 h) 
 
 (A) Control group, which was dosed with PBS only; (B) APAP (400 mg/kg) 4 h only 












Figure 6.9. Histopathologic assessment of liver sections from untreated and treated 
C57BL/6 mice with APAP (400 mg/kg for 4 h) 
 
(A) Control group, which were dosed with PBS only; (B) APAP (400 mg/kg) 4 h only 
group; (C) APAP + NAC (106 mg/kg) group, arrows indicate regions of medium to small 
hepatocellular cytoplasmic vacuoles; and (D) APAP + NACA (106 mg/kg) group arrow 









Figure 6.10. Histopathologic assessment of liver sections from untreated and treated 
C57BL/6 mice with APAP (300 mg/kg for 4 h) 
(A) Control group, which were dosed with PBS only; (B) APAP (400 mg/kg) 4 h only 
group, cellular necrosis noted by arrows and cytoplasmic vacuoles noted by arrow heads; 






Figure 6.11. Histopathologic assessment of liver sections from untreated and treated 
C57BL/6 mice with APAP (300 mg/kg for 24 h) 
 
(A) Control group, which were dosed with PBS only; (B) APAP (400 mg/kg) 4 h only 
group, cellular necrosis noted by arrows and cytoplasmic vacuoles noted by arrow heads; 
















































Figure 6.12. Histopathologic 
hepatic lesion scores from untreated 
and treated C57BL/6 mice (n=3) 
   
(A) APAP (400 mg/kg for 4 h), (B) 
APAP (300 mg/kg for 4 h), and (C) 
APAP (300 mg/kg for 24 h). Post 
treatment with NAC or NACA (106 
mg/kg) at 1.5 h after APAP 
treatment in all treatment groups. 
Bar represents mean ±SD lesion 
score per group. (#: different from 




6.2 DISCUSSION  
APAP toxicity is one of the most common causes of drug-induced hepatotoxicity 
worldwide that lead to excessive treatment and high hospitalization costs every year. 
Oxidative stress has been hypothesized by many researchers to play an important role in 
the etiology of APAP toxicity.[121-123] It is defined as an imbalance between the 
production of reactive oxygen species (ROS) and endogenous antioxidants and repair 
capacity. Depletion of GSH by approximately 70% is the initial step in APAP 
hepatotoxicity, [51, 52] which is explained by the conjugation of GSH with the electrophilic 
toxic metabolite of APAP (NAPQI). Based on the mechanism of toxicity, the treatment 
focus is on a compound that acts as an antioxidant and stimulates GSH synthesis. The 
only approved antidote for APAP toxicity, NAC, relies on restoring the GSH level and 
antioxidant properties to restrict liver damage. NAC has quite a narrow therapeutic 
window and, because of its poor bioavailability, larger doses and longer treatment times 
are required.[24] In a clinical setting, NAC is administered at 150 mg/kg over 15 min, 
followed by 50 mg/kg over 4 h, and then 100 mg/kg over 16 h, so the total dose is 300 
mg/kg.[17] For animal studies, 300 - 1200 mg/kg (high doses) are reported as an effective 
range for NAC dosing.[13, 124] Chieko Saito et al.[13], Marcus V. Terneus et al.[125], and 
Francesco Di Pierro et al [126] reported a direct dose response relationship using NAC and 
observed that a larger dose of NAC was sufficient to supply cysteine for GSH synthesis, 
promote recovery of the liver, and primarily maintain mitochondrial GSH levels. It 
improved mitochondrial bioenergetics as well. However, larger doses of NAC are 
associated with increased risk of side effects. Therefore, we studied the protective effects 
of NACA (which has higher bioavailability than NAC) against APAP-induced 
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hepatotoxicity and compared its effects with those of NAC. The serum levels of ALT and 
GDH were the main indices used to detect liver and mitochondria injury, respectively, 
while the levels of GSH, GSSG, and MDA were used as indicators of oxidative stress. In 
this study, I evaluated the role of NACA in counteracting the hepatotoxicity in an in vivo 
model, and these findings were compared with the effects of NAC.  
 My study show a significant decrease in the GSH level in the liver after a toxic 
dose of APAP, which is regarded as a first step in toxicity and induction of oxidative 
stress. This reduction in the level of GSH, after toxic administration of APAP, may have 
been due to its conjugation with NAPQI during the detoxification pathway. My results 
are in line with previous studies that reported a decrease in GSH levels following APAP 
treatment.[124-129] In addition to decreases in GSH, increases in intracellular GSSG have 
been reported during the recovery phase of cellular GSH content after APAP 
treatment.[57, 60, 72] A decrease in GSH, in conjunction with an increase in GSSG, 
following APAP treatment, is consistent with previous reports.[24, 125] Post-treatment with 
NACA significantly increased GSH in the APAP-treated group, while NAC did not, 
indicating that NACA was significantly better than NAC. These results indicated that 
NAC did not replenish the GSH levels at the dose given, which could be attributed to the 
lower bioavailability of NAC, when compared to that of NACA. My results are in line 
with one other study that compared two different doses of NAC (1.25 mmol/kg vs. 7.35 
mmol/kg) in APAP-induced toxicity and reported no enhancement in GSH levels when 
1.25 mmol/kg of NAC were administered to C57BL/6 mice.[125] Furthermore, in my 
study, I used 106 mg/kg, which corresponds to 0.65 mmol/kg of NAC, a dose that is 
much lower than that used by Terneus et al.[125] The protective effects of NACA can 
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possibly be explained by its ability to supply cysteine for GSH biosynthesis, in addition 
to reducing extracellular cystine to cysteine through conversion of GSSG to GSH by a 
nonenzymatic thiol disulfide exchange, and by restoring GR activity.[28] Changes in levels 
of either GSH or GSSG, or both, affect the GSH/GSSG ratio. GSH/GSSG represents a 
clear picture of the oxidative state in the body and is used as a good indicator of oxidative 
stress.[130] In agreement with previous studies, my results show a dose-dependent 
decrease, [121] as well as the effect of time, [22] in the GSH level.  Dose-dependent effects 
can be explained by increased production of NAPQI, which concomitantly depletes GSH 
by conjugation. The low dose of APAP (300 mg/kg) did not affect the level of GSSG; 
however, a significant reduction in GSH also resulted in a significant reduction in the 
GSH/GSSG ratio. A drastic decrease in the ratio of GSH/GSSG post a 400 mg/kg dose of 
APAP could be attributed to the higher concentration of NAPQI, resulting in further 
depletion of GSH. Furthermore, binding of excess NAPQI to mitochondrial proteins 
leads to increased production of free radicals which, in turn, may be reduced by GSH 
resulting in a higher concentration of GSSG.  By increasing the period of exposure to 
APAP from 4 h to 24 h, the GSH level was restored to the control level, which is 
consistent with a previous study that showed a similar decrease in hepatic GSH at 4 h and 
a regeneration at 24 h after APAP administration.[22] Marel R. et al. showed in their paper 
an increased level of GSH, instead of a decrease, after an exposure of APAP for 24 h, and 
they explained that as an attempt to restore the lost oxidative balance.[19] The disruption 
of GSH/GSSG ratio at 24 h post APAP injection is attributed to the higher GSSG levels 
and is not due to disruption of the GSH levels. NAC and NACA acted equally to restore 
this GSH/GSSG ratio, possibly by directly scavenging ROS and, thereby, lowering the 
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formation of GSSG. The low bioavailability of NAC was overcome by restoration of the 
hepatic GSH level in the 24 h design study. 
Many studies have shown that treatment of rodents with different doses and 
durations of NAC decreased the hepatotoxicity induced by APAP to various levels of 
severity. Chieko Saito et al. showed in their paper the positive effect of using a high dose 
of NAC (318 mg/kg) for increasing GSH and ATP levels and for decreasing ALT 
activity, in comparison with a low dose of NAC (106 mg/kg), with both being measured 
6 h after APAP dosing.[13] In addition, Marcus V. Terneus et al.[125] reported that a high 
dose of NAC (1200 mg/kg) was able to restore the GSH level back to the control level, 
while a low dose (204 mg/kg) did not induce any change in the GSH levels when 
measured 4 h after APAP injection. These studies support my hypothesis that, NACA 
treatment, because of its high bioavailability, we will have the benefits provided by a 
high dose of NAC without actually using such a high dose. 
GR is a key antioxidant enzyme involved in the maintenance of cellular GSH 
homeostasis under normal physiological conditions. It reduces GSSG to GSH, which 
allows cells to detoxify more NAPQI and free radicals. A reduction in the activity of GR 
was observed with APAP treatment and is documented in literature.[131, 132] Some studies 
relate this impairment in the activity of antioxidant enzymes to excessive production of 
NAPQI, resulting in generation and accumulation of ROS and concomitant loss of GSH, 
which directly affects the activity of GSH-related enzymes.[133, 134] Furthermore, the 
reduced activity of GR could also be attributed to a decrease in its cofactor, NADPH, 
which has reportedly been used for the reduction of NAPQI to APAP.[12, 135] Decreased 
activity of GR has a deleterious effect, resulting in accumulation of GSSG that leads to 
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further oxidative stress. My studies show a dose response effect of APAP on GR activity. 
The reduction in GR activity could be attributed to the oxidation of crucial sulfhydryl 
groups in GR, which are important for GR activity. Post-treatment with NACA 
significantly restored GR activity; however, a similar dose of NAC was not effective. 
After a 24-h exposure time the tissue might be defending against oxidative stress by de 
novo GSH synthesis, as well as regeneration via reduction of GSSG to GSH by 
enhancing the activity of GR. The enhancement in GR activity could be attributed to an 
enhanced supply of NADPH as well as reduction of crucial sulfhydryl groups in GR. 
However, this enhancement in GR activity might not be sufficient to convert all of the 
GSSG back to GSH. 
Depletion of GSH sets off a cascade of further oxidative damage. Excess NAPQI 
binds to cellular protein (mainly mitochondrial protein) that leads to mitochondrial 
dysfunction that inhibits oxidative phosphorylation, and depletes adenosine triphosphate 
(ATP), that leads to mitochondrial oxidative stress.[58, 132] NAPQI binding to 
mitochondrial proteins and mitochondrial dysfunction are the central mechanisms of 
toxicity. The severe depletion of mitochondrial GSH reported here is in line with the 
literature.[13, 73, 113] The role of mitochondrial oxidative stress in APAP toxicity is 
documented, and evidence for superoxide and peroxynitrite selective formation in the 
mitochondria is reported in the literature, [58] which supports my premise that a significant 
reduction in the GSH/GSSG ratio indicates oxidative stress.[130] NAC has a limited 
capacity to increase the GSH level, but administration of NACA at an equimolar 
concentration is able to restore the depleted mitochondrial GSH level, which scavenged 
the free radicals (as confirmed by significant restoration of the GSH/GSSG ratio) that 
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may have attenuated cell injury. However, scavenging of the free radicals is not the only 
NAC mechanism that protects against APAP toxicity in the mitochondria. Excess 
cysteine that is not needed in GSH synthesis is degraded and used as an energy substrate 
in the TCA cycle to support mitochondrial energy production.[13] To further support my 
results of mitochondrial oxidative stress and dysfunction, I measured the levels of serum 
GDH (an enzyme of the mitochondrial matrix that is largely expressed in the liver). I 
observed elevated levels of GDH, which is in agreement with previous studies and 
indicates mitochondrial damage.[32, 136] Post-treatment with NACA is able to significantly 
decrease GDH levels while NAC cannot. An equidose of NACA is better than that of 
NAC in providing a sufficient amount of GSH to overcome protein binding. My previous 
paper reported that mitochondrial dysfunction was detected in a HepaRG cell model after 
APAP toxicity, [26] which is supported by other studies as well.[32, 46, 132] 
The liver tissue contains a large amount of polyunsaturated fatty acids (PUFAs), 
which are susceptible to peroxidative damage.[137] NAPQI binding to a sulfhydryl group 
of proteins and the overproduction of free radicals in APAP toxicity may have prompted 
lipid peroxidation and depletion of antioxidant enzymes and, consequently, an increase in 
the MDA content. MDA is a biomarker of lipid peroxidation and its elevation during 
APAP toxicity is reported in the literature.[20, 22, 33, 121] Lipid peroxidation is a multi-step 
process requiring the initiation of a chain reaction and propagation. This peroxidation 
affects the membrane fluidity which results in severe cellular dysfunction and complete 
destruction of the cell membrane and cell death.[129, 138] Glutathione peroxidase (GPx) 
plays a major role in defense mechanism by reducing lipid peroxidation. GPx inhibits 
lipid peroxidation by reducing lipid peroxides to their corresponding alcohols in the 
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presence of GSH as a substrate.[48] A reduced level of GSH, as a consequence of a high 
level of NAPQI, may have affected GPx levels, and led to the accumulation of MDA.[75] 
However, post-treatment with NACA interrupted this chain reaction of lipid peroxidation 
by supplying an adequate amount of GSH (GSH precursor), a substrate for GPx, to 
effectively reduce MDA levels and scavenge the very reactive hydroxyl and lipid peroxyl 
radicals. Interestingly, NAC was not able to supply an adequate amount of GSH at this 
low dose. 
The end point in the hepatotoxicity induced by APAP is the necrosis in the 
hepatic cells, which was confirmed by histological and macroscopic evaluation and by 
measuring liver function enzymes. ALT is the enzyme present in hepatocyte cytoplasm; 
however, damaged hepatocytes lead to increases in the level of ALT in the serum. This is 
a reliable marker and a sensitive indicator of liver injury because of its 90% presence in 
the liver.[76, 119, 139] My results showed a very large increase in ALT activity in the APAP-
treated group, which was consistent with previous studies in which researchers reported 
elevations in serum transaminases following a toxic dose of APAP.[57, 116, 125] This is a 
significant criterion for assessing the positive effects of any hepatoprotective drugs that 
can preserve normal physiological functions, assure membrane stability that may have 
been disturbed, and promote regeneration of liver cells.[131] NACA successfully restored 
the transaminase enzyme to normal levels, stabilized the membrane, and allowed 
regeneration of liver cells. NAC, however, significantly restored this enzyme after 
administration of a lower dose of APAP (300 mg/kg), but was not able to do this with 




To gain further insight into the protective role of NAC/NACA, histological 
evaluations were performed. Evaluations showed centrilobular necrosis upon APAP 
treatment. This was consistent with literature reports of APAP toxicity.[23-25] 
Interestingly, I found that livers of the NAC- and NACA-treated mice had histologic 
lesion scores similar to the untreated control group, despite having higher levels of the 
serum ALT.  Although serum ALT activity is considered a highly specific and sensitive 
marker of hepatotoxicity, it may have given us a false positive result. Furthermore, to 
explain the discrepancy in our ALT activity data with histological data, an additional 
biomarker, GDH activity, was used which improved specificity for liver function, as 
compared to the use of serum ALT activity alone. Serum GDH activity is more specific 
for the liver and would eliminate the risk of false results.[140]  
Although, histopathology is a valuable tool that is frequently used to 
microscopically visualize cellular damage, the ability to adequately assess cellular 
damage utilizing this method depends on the amount of tissue injured, sample size, and 
tissue sectioning during histopathological preparation. This could have resulted in the 
discrepancy between our biochemical and histological data.  Therefore, histopathologic 
assessment is commonly used in conjunction with other molecular based tests.  As 
detection of serum ALT and GDH assays is independent of tissue sample size and 
sectioning, these assays may be more sensitive to changes in hepatocellular injury.  
Furthermore, for this study, a small portion of the liver samples was evaluated for 
histopathologic lesions and, therefore, the ALT and GDH assays may have been more 
representative of the molecular hepatocellular changes that occurred in the treatment 
groups. Despite elevations in ALT and GDH, as compared to that of normal control 
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animals, the NACA-treated group was statistically lower than the NAC-treated group, 
indicating better hepatocellular protection by NACA. Furthermore, the discrepancy in the 
histological data due to small sample size can be explained by the acinus concept. 
According to the acinar unit concept,[141] the gradient of blood supply and the presence of 
CYP in zone 3 determined the extent of damage within a single section of the same 
specimen of the liver. This gradient would make the histological evaluation less sensitive 
than that of the biochemical assay of a small sample size. 
 The maximum toxicity of APAP reported by investigators was at 4 to 6 h after 
administration; then, by 24 h, the liver started to regenerate.[22] My results were in 
agreement with that, starting from the level of GSH that was earlier depleted as a result of 
NAPQI formation, until the end point of toxicity (the level of ALT that indicates cell 
necrosis), which showed a maximum toxicity at 4 h compared to that at 24 h. That 
explains the equal effectiveness of NAC and NACA at 24 h, when a smaller dose was 
needed to counteract toxicity. However, NACA appeared to be more potent than NAC in 
reversing oxidative damages induced by APAP at 4 h.  
The disadvantage of NAC’s low bioavailability was more pronounced after 4 h of 
APAP administration, and this low dose (106 mg/kg) helped to highlight the advantage of 
using NACA. NACA was very efficient in scavenging free radicals, stimulating 
antioxidant enzyme, providing cysteine to stimulate ϒ-glutamylcysteine synthetase (the 
rate limiting step in GSH synthesis), all of these with this low dose. 
In summary, this study clearly demonstrates that APAP hepatotoxicity was 
alleviated and the animals were rescued by NACA treatment. My data show that, at a 
dose of 106 mg/kg, NACA is more effective than NAC at combating APAP-induced 
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toxicity. This effectiveness may be attributed to NACA’s higher bioavailability, as 
compared to that of NAC. The data indicates that NACA was more effective than NAC at 
a lower dose and, therefore, may be developed into a potential antidote for APAP-
induced toxicity, with potentially lower or no indication of the side effects that have 
traditionally been associated with higher doses of NAC. Furthermore, the higher 
bioavailability of NACA may also help widen the therapeutic window for the treatment 


















   7.1.1 Effect of NAC/NACA on Intracellular Levels of GSH. Intracellular 
depletion of GSH is reported as a first step in APAP-induced toxicity, so we studied the 
effect of APAP on the level of GSH. The results showed a significant decrease in the 
GSH levels (to approximately 66% of the control) after treatment with 400 mg/kg of 
APAP for 4 h (Figure 7.1A). Interestingly, the NAC treatment group was not effective in 
significantly increasing the level of GSH at this low dose (106 mg/kg). However, the 
NACA treatment group showed a considerable increase in the GSH level to that of the 
control level.  
The dose and time dependent toxicity of APAP were evaluated by using a lower 
dose (300 mg/kg) and two different sacrificing times (4 h and 24 h). The GSH level was 
reduced to 79% of the control with the dosing of 300 mg/kg APAP for 4 h (Figure 7.1 B). 
The effects of NAC and NACA with this dose were similar to the effects with a higher 
dose (400 mg/kg) in which NACA was able to show a positive effect in restoring the 
GSH level back to that of the control level, while NAC was not be able to make any 
significant change in this level at this dose (106 mg/kg). A 24 h treatment time with 300 
mg/kg APAP depleted the GSH level to around 56.7% of the control level (Figure 7.1 C).  
NAC and NACA showed similar enhancement of GSH levels back to the control level. 
            7.1.2 Effect of NAC/NACA on Intracellular Levels of Cysteine. The cysteine 
level was depleted to around 48% of the control level in the APAP-treated group (400 
mg/kg for 4 h). Post treatment with NACA was able to significantly restore the cysteine 
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level, as compared to the level in the APAP-treated only group. Post treatment with NAC 
was able to increase the cysteine level; however, it was not significant when compared 
with that of the APAP-only treated group (Figure 7.2).  
            7.1.3 Effect of NAC/NACA on Creatine Kinase Level. The creatine kinase level 
in the serum was significantly elevated after dosing with APAP for 4 h, indicating 
nephrotoxicity (Figure 7.3). NACA post treatment was able to greatly decrease this 
elevation, while NAC post treatment was not effective.  
            7.1.4 Effect of NAC/NACA on Blood Urea Nitrogen Level. The blood urea 
nitrogen level increased significantly following dosing with 400 mg/kg of APAP for 4 h. 
NACA post treatment was able to significantly decrease this elevation, while NAC post 








            
































































































































































Figure 7.1. Kidney 
glutathione (GSH) levels 
 
C57BL/6 mice injected 
with (A) APAP (400 
mg/kg) for 4 h, (B) APAP 
(300 mg/kg) for 4 h, and 
(C) APAP (300 mg/kg) for 
24 h. Post treatment with 
NAC or NACA (106 
mg/kg) at 1.5 h after 
APAP treatment of all 
treatment groups. Values 
represent mean ±SD (n=6) 
(*: different from the 
control group, #: different 
from the APAP group, and 
^: different from APAP+ 





Figure 7.2. Kidney cyestine (Cys) levels 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h. Post treatment with NAC or 
NACA (106 mg/kg) at 1.5 h after APAP treatment in all treatment groups. Values 
represent mean ±SD (n=6) (*: different from the control group, #: different from the 

























































Figure 7.3. Serum creatine kinase activity 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h, followed by treatment with 
NAC or NACA (106 mg/kg) at 1.5 h after APAP treatment. Values represent mean ±SD 





















































Figure 7.4. Serum blood urea nitrogen (BUN) level 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h. Post treatment with NAC or 
NACA (106 mg/kg) at 1.5 h after APAP treatment in all treatment groups. Values 
represent mean ±SD (n=6) (*: different from the control group, #: different from the 

















































The kidney is the second organ that may be affected by an APAP overdose and 
nephrotoxicity has been reported in many studies.[62-65] Although nephrotoxicity is less 
common than hepatotoxicity with an APAP overdose, many reports have associated the 
renal effect with severe hepatotoxicity,[37] and renal damage can occur, even in the 
absence of liver injury.[68, 70] Generation of ROS has been proposed as a mechanism by 
which many chemicals can induce nephrotoxicity, and oxidative stress remains as the 
most important cause in the case of APAP toxicity.[79-81] Studies have shown that an 
overdose of APAP induces lipid peroxidation and represses the antioxidant defense 
system of the kidney.[63, 79, 80] A mechanism, similar to that of hepatotoxicity, was 
proposed for the nephrotoxicity that is mainly related to the toxic metabolite of APAP 
(NAPQI), which binds covalently to proteins, causing cell death.[22, 63] The mechanism of 
toxicity in the kidney is less clearly understood, as compared to that in the liver. 
Several potential mechanisms of renal toxicity are proposed in the literature. 
Those include the CYP pathway, prostaglandin synthase, deacetylase enzymes, and 
APAP-GSH conjugate excretion pathway (all of these pathways are explained in detail in 
section 2.4.1). NAC is the only approved antidote for APAP toxicity, and its mechanism 
of protection is based on the use of large doses to replenish GSH, that can scavenge 
NAPQI (if given early), or to recover GSH and scavenge the reactive oxygen and 
nitrogen radicals.[11] In addition, it provides excess amino acid to serve as energy 
substrates in mitochondria. NAC is not always effective in treating nephrotoxicity-
induced by APAP, [67, 69, 70] although it is effective in cases of renal failure caused by 
toxic compounds such as gentamycin[142] and ifosfamide.[143] So, it is important to 
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introduce another compound which is effective against APAP-induced renal toxicity. 
NACA’s effect in APAP-induced nephrotoxicity was biochemically evaluated in this 
study, and showed promising results. 
In my results, NACA treatment effectively protected against nephrotoxicity 
induced by APAP overdoses in mice. This evidence was supported by significant 
improvement in the disturbed biochemical parameters. Administration of APAP-induced 
nephrotoxicity was manifested by a significant increase in the serum BUN [67, 70, 80] and 
creatine kinase enzyme activity (CK) [144] that indicated renal dysfunction (proved in 
many animal studies). CK catalyzed the conversion of creatine and utilized adenosine 
triphosphate (ATP) to create phosphocreatine (PCr) and adenosine diphosphate (ADP). 
Clinically, creatine kinase was assayed in blood tests as a marker of damage in CK-rich 
tissues, such as in a heart attack, severe muscle breakdown, and acute renal failure. Blood 
urea nitrogen that is found in liver protein is usually excreted in the urine. Renal diseases 
that are predicted based on the accumulation of BUN (where the rate of production 
exceeded the rate of clearance) make it a more reliable marker for renal function. 
However, these increases were reversed by the administration of NACA, while a similar 
dose of NAC was not effective.  
It has been reported that intracellular GSH plays a significant role in APAP-
induced nephrotoxicity.[63, 70, 79] The GSH level, which is significantly depleted following 
an APAP overdose, is used to detoxify NAPQI (toxic metabolite of APAP). The excess 
NAPQI then binds to cellular protein leading to renal injury. As a consequence of GSH 
depletion, there is a decrease in the detoxification of NAPQI (which increases its binding 
to macromolecules), in addition to serious harmful effects on cellular balance (which may 
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increase the toxic effects of the reactive metabolite). NAC, a GSH pro-drug approved for 
APAP hepatotoxicity, has not shown clear benefits for renal toxicity. Although some 
papers show that it might help in the treatment,[22] others indicate that it does not provide 
any benefit. [67, 69, 70] In this study, we show that NACA successfully increases the GSH 
level in kidneys.  
ϒ-glutamyltranspeptidase (ϒ-GT) activity in the kidneys is much higher than that 
in the liver, so that GSH (as a substrate of ϒ-GT) is degraded more rapidly in the 
kidneys.[71, 145] This may explain the low GSH and high cysteine levels in the kidneys, 
where an APAP overdose led to significant decreases in the cysteine levels. This decrease 
might have resulted from the conjugation of the reactive metabolite with the SH group in 
the cysteine, [136] as supported by the study of L. J. Fischer et al. [146] This study shows a 
high concentration of cysteine conjugates in the kidneys. Furthermore, cysteine might be 
delivered to the blood under oxidative stress conditions that are induced by an APAP 
overdose. Daniela Giustarini et al.[147] show in their study that oxidative stress induces a 
reversible flux of cysteine from tissue to the blood. NACA post-treatment was able to 
restore this level back to the control level. 
NACA may act as an antioxidant and scavenging agent for free radicals (which 
have a role in the pathogenesis of APAP-induced nephrotoxicity) and NAPQI, by directly 
binding with them and preventing their binding to cellular proteins. It may reduce GSSG 
back to GSH by non-enzymatic disulfide exchange and, thereby, increase the GSH level 
indirectly because the kidneys cannot synthesize GSH from its precursors, but takes it 
from circulation, when required.[70, 79, 144] In addition, NACA may help by providing more  
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cysteine in the cells, which may help in the detoxification process. Further studies in this 
























8. OTHER ORGANS TOXICITY 
 
8.1. BRAIN TOXICITY RESULTS 
8.1.1 Effect of NAC/NACA on Intracellular Levels of GSH, GSSG, and 
GSH/GSSG. Dosing with 400 mg/kg of APAP did not affect the levels of GSH and 
GSSG and, thereby, the GSH/GSSG ratio (Figure 8.1). As the brain’s GSH level was not 
affected by APAP dosing, post-treatment with NAC/NACA did not provide any benefit.     
8.1.2 Effect of NAC/NACA on the Activity of GR. The GR levels of the brain 
were not significantly changed in any of the treatment groups, as the dosing of 400 mg/kg 
APAP did not have a noticeable effect (Figure 8.2).  
8.1.3 Protective Effect of NAC/NACA on Lipid Peroxidation. None of the 
groups showed any significant change in the levels of MDA after a 400 mg/kg APAP 































Figure 8.1. Brain glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG ratio 
levels 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio levels in which 
C57BL/6 mice injected with APAP 
(400 mg/kg) for 4 h, followed by 
NAC or NACA (106 mg/kg) at 1.5 
h after APAP treatment of all 
treatment groups. Values represent 


















































































































































Figure 8.2. Brain glutathione reductase (GR) activity 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h, followed by NAC or NACA 
(106 mg/kg) at 1.5 h after APAP treatment of all treatment groups. Values represent 















































Figure 8.3. Brain malondialdehyde (MDA) levels 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h, followed by NAC or NACA 
(106 mg/kg) at 1.5 h after APAP treatment of all treatment groups. Values represent 























































8.2. SPLEEN TOXICITY RESULTS 
8.2.1 Effect of NAC/NACA on Intracellular Levels of GSH, GSSG, and 
GSH/GSSG. Intracellular depletion of GSH was observed, which was reduced to 42.2% 
of the control level, following 400 mg/kg dosing of APAP. Interestingly, a low dose (106 
mg/kg) of NAC was not effective in significantly increasing the levels of GSH. However, 
the NACA treatment group showed a major increase in the GSH level, as compared to 
that of the control. Interestingly no significant changes were observed in either the GSSG 
levels or the GSH/GSSG ratios of the treatment groups (Figure 8.4).  
8.2.2 Effect of NAC/NACA on the Activity of GR. Dosing with 400 mg/kg of 
APAP showed a significant reduction in GR activity by approximately 70% of the control 
level. NACA post-treatment was able to restore the activity to that of the control, while 
NAC was not able to induce any major change in GR activity (Figure 8.5).  
8.2.3 Protective Effect of NAC/NACA on Lipid Peroxidation. MDA levels 






































Figure 8.4. Spleen glutathione 
(GSH), glutathione disulfide 
(GSSG), and GSH/GSSG ratio 
levels 
 
(A) GSH, (B) GSSG, and (C) 
GSH/GSSG ratio levels in 
which C57BL/6 mice injected 
with APAP (400 mg/kg) for 4 h, 
followed by NAC or NACA 
(106 mg/kg) at 1.5 h after APAP 
treatment of all treatment 










































































































































Figure 8.5. Spleen glutathione reductase (GR) activity 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h, followed by NAC or NACA 
(106 mg/kg) at 1.5 h after APAP treatment of all treatment groups. Values represent 






















































Figure 8.6. Spleen malondialdehyde (MDA) levels 
 
C57BL/6 mice injected with APAP (400 mg/kg) for 4 h, followed by NAC or NACA 
(106 mg/kg) at 1.5 h after APAP treatment of all treatment groups. Values represent 


























































Although, APAP overdose is known to induce hepato- as well as nephrotoxicity, 
it is generally not considered to be toxic to other organs. However, since most epithelial 
tissues possess the enzymes necessary to produce the APAP toxic metabolite, 
extrahepatonephric, APAP toxicity needs to be evaluated. Liver dysfunction results in the 
development of hepatic encephalopathy by the accumulation of ammonia and formation 
of ROS, which affects the antioxidant capacity of the whole organism.[148] Brain tissue is 
highly susceptible to oxidative stress, owing to its high content of unsaturated fatty acids, 
high oxygen consumption, and poorly developed oxidative defense mechanisms.[149] The 
spleen is the largest peripheral lymphatic organ and plays an important role in adaptive 
immune response. 
 L. J. Fischer et al.[146] show in their research that the covalent binding of reactive 
metabolite of APAP was highest in the liver, followed by the extent of its presence in the 
kidneys (one-fifth of that in the liver), but it was very low in the brain and did not 
increase with time after an APAP dose. In another study, the authors reason that there is 
low covalent binding of NAPQI in the brain because of the relative low activity of CYP 
there (as compared to that in the liver), which activates APAP, even though the level of 
unchanged APAP is high in the brain (substrate for potential toxicity). [150] This is in 
contrast to several other studies that indicate that rats have an isoform of CYP (CYP2E1) 
that is responsible for NAPQI formation, which forms directly in brain tissue following 
APAP’s crossing of the blood brain barrier.[149] Kamilla Blecharz-klin et al.[148] observed 
changes in the levels of neural amino acid in animals treated with APAP, which may be 
linked with a wide range of pharmacological effects of APAP on the central nervous 
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system, and may play a role in the pathology of some neurobehavioral disturbances. In 
contrast, Susan G et al. shows, by using immunohistochemical methods, that the brain 
and spleen do not exhibit APAP-induced toxicity or covalent binding and, also, do not 
express CYP2E1.[151] Spielberg and Gordon [152, 153] show that APAP could cause 
lymphocyte necrosis in vitro following drug activation by added microsomal enzymes. 
This is consistent with the observation of splenic lymphoid necrosis in the Michael E. 
Placke et al. study.[154] Another study, by Mary Jane Masson, [155] shows that a 
hepatotoxic dose of APAP is followed by a lymphocyte loss that may be due to apoptosis 
in the spleen, thymus, and hepatic draining lymph nodes. Literature review shows many 
controversial results of the effects of an APAP overdose on the spleen and brain.   
 In this study, APAP did not induce any noticeable toxicity in the brain although it 
significantly decreased the GSH and GR levels in the spleen. Michele Hinerasky[149] 
reports decreases in GSH levels associated with increases in lipid peroxidation in the 
brain but, in that study, higher doses of APAP were used to induce this neurotoxic effect 
than are used in this study. 
 It is possible that chronic administration of APAP, or its concurrent use with a 
modifying factor, may enhance its toxicity and have a role in spleen and brain toxicity. 
Findings from other papers suggest that the combination of APAP and ethanol may 
increase the inhibition of antibody production caused by ethanol alone.[156] They show 
that APAP, combined with ethanol, significantly enhances the reductions of phagocytic 
activity and circulating leukocyte counts caused by ethanol alone. Further studies are 
required wherein higher doses or longer exposure times may help clarify the 




 The most common painkiller (APAP) can be a “real” killer if it is not used 
properly. The primary toxicity of APAP results from drug metabolism in both the liver 
and extrahepatic tissue. Most of the drug is metabolized by glucuronidation and sulfation 
and only about 5% is metabolized by CYP to form NAPQI (the toxic metabolite). At 
therapeutic doses, NAPQI is reduced by GSH and is subsequently excreted as 
mercapturic acid. In the case of an overdose, GSH is depleted and more NAPQI is 
accumulated. These electrophilic intermediates then form adducts with cellular proteins 
that disrupt homeostasis and result in tissue necrosis and organ dysfunction. This has 
been demonstrated in both the liver and extrahepatic tissue in animal models. The 
mechanism of toxicity is well described for the liver, but is less clearly understood for the 
kidneys, which have several potential mechanisms.   
The liver is the central organ in the metabolism of almost all drugs, and the 
kidneys, which contain active enzyme systems capable of metabolically activating drugs, 
are the site of excretion. Studies are being conducted throughout the world to search for 
and identify protective molecules that can provide maximum protection for the liver and 
kidneys, as well as for other organs, to assure that there are very few (or no) side effects 
to these crucial functions of the body. GSH serves as an important antioxidant for cells 
and its altered level is considered as an indicator of oxidative damage. The essential role 
of GSH in maintaining the redox status in a cell makes it an attractive potential 
therapeutic agent in oxidative stress-related conditions. The efficacy of the GSH prodrug, 
NACA, is increased due to its higher bioavailability which, in turn, would reduce the 
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toxicity associated with higher doses of NAC. Various studies indicate that NACA acts 
by restoring GSH levels, which allow cells to combat oxidative stress.  
Although NAC is the treatment of choice in APAP-induced toxicity, fairly high 
doses and longer treatment times are required due to its poor bioavailability. This study 
demonstrates that NACA is better than NAC and has the potential to be developed into a 
viable therapeutic agent against APAP-induced toxicity.  Thus, not only the effectiveness 
of NACA, but also the potential for reduced dosage and a wider therapeutic window 
might support its use for treating patients. As a result of growing interest, use of NACA 
for the treatment of diseases and conditions associated with oxidative stress was patented 













10. FUTURE DIRECTION 
 Based on the results of this project, with regard to NACA’s effect in APAP 
toxicity, a series of experiments should be performed in the future to gain further insight. 
This study has stimulated our thinking and guided us toward recommendations for the 
future direction of our research. These include: 
- Evaluate the antidotal effect of NACA against APAP-induced toxicity, after 
delayed application, and compare findings with the effect of NAC. 
For this study, C57BL/6 mice will be divided into six groups (n=6): PBS, NAC, 
NACA, APAP, APAP+NAC, and APAP+NACA. The mice will be administered 400 
mg/kg of APAP, followed by NAC/NACA (106 mg/kg) at different time points (1.5, 4, 6, 
12, and 20 h). The animals will be sacrificed 24 h after APAP dosing. Blood will be 
drawn and centrifuged to get serum. The tissues will be frozen at -80°C for later analysis. 
- Evaluate the antidotal effect of NACA against APAP-induced toxicity and 
compare it with NAC by using a protocol to mimic the one approved for NAC in 
clinical practice. 
For this study, C57BL/6 mice will be divided into six groups (n=6): PBS, NAC, 
NACA, APAP, APAP+NAC, and APAP+NACA. The mice will be administered 400 
mg/kg of APAP (i.p), followed by p.o administration of NAC/NACA on a dosing 
schedule of 140 mg/kg at 1.5 h after an APAP dose, followed by 17 doses of 70 mg//kg 
each, every 4 h. The animals will be sacrificed 1 h after the last NAC/NACA dose. Blood 




- Evaluate the effect of NACA on the regeneration of liver tissue over time and 
compare findings with the effect of NAC. 
For this study, C57BL/6 mice will be divided into six groups (n=10): PBS, NAC, 
NACA, APAP, APAP+NAC, and APAP+NACA. The mice will be administered 400 
mg/kg of APAP (i.p), followed by NAC/NACA (106 mg/kg) orally on a dosing schedule 
of 140 mg/kg 1.5 h after an APAP dose, followed by 17 doses of 70 mg//kg each, every 4 
h. A blood sample will be drawn from the tail every day for 2 weeks to check the liver 
function enzymes (ALT and GDH). The samples will be withdrawn through a temporary 
cannula to reduce the pain and stress of the animals. If a vein is not visible, the tail will 
be dipped into warm water (40°C) and a local aesthetic cream will be applied to the 
surface of the tail 30 min before the experiment. Because of repeated blood sample 
collection, fluid replacement may be required. Lactated Ringer’s solution (LRS) will be 
used, as recommended by the National Institutes of Health. 
An alternative method to collect blood samples is the retro-orbital blood 
collection, in which anesthesia is required. 
    -   Explore the nephrotoxicity induced by APAP by adding more parameters to 
evaluate the effects of NACA as GSSG, MDA, and antioxidant enzymes. 
     -     Focus on brain and spleen toxicity induced by APAP.  
In this study, the dose of APAP will be increased to 600 mg/kg, and the exposure 
time will be extended to 12 h. The redox status will be evaluated by measuring GSH, 
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